Published in final edited form as:

ChemMedChem. 2008 March ; 3(3): 487–501. doi:10.1002/cmdc.200700314.

Chemistry, Biology, and QSAR Studies of Substituted Biaryl Hydroxamates and Mercaptoacetamides as HDAC inhibitors - Nanomolar Potency Inhibitors of Pancreatic Cancer Cell Growth

Alan P. Kozikowski [Prof.]^{*,[a]}, Yufeng Chen^[a], Arsen M. Gaysin^[a], Doris N. Savoy^[b], Daniel D. Billadeau [Prof.]^[b], and Ki Hwan Kim^[a]

[a] *Drug Discovery Program, College of Pharmacy University of Illinois at Chicago 833 S. Wood St., Chicago, Illinois 60612, USA.*

[b] *Department of Immunology and Division of Oncology Research College of Medicine, Mayo Clinic 13-42 Guggenheim, 200 First Street SW, Rochester MN 55905, USA*

Abstract

The histone deacetylases (HDACs) are able to regulate gene expression and inhibitors of the HDACs (HDACIs) hold promise in the treatment of cancer as well as a variety of neurodegenerative diseases. To investigate the possibility to achieve some measure of isoform selectivity in the inhibition of the HDACs, we prepared a small series of 2,4'-diaminobiphenyl ligands functionalized at the para-amino group with an appendage containing either a hydroxamate or a mercaptoacetamide group and coupled to an amino acid residue at the ortho-amino group. A smaller series of substituted phenylthiazoles was also explored. Some of these newly synthesized ligands show low nM potency in the HDAC inhibition assays and display micromolar to low nanomolar IC₅₀ values when tested against five pancreatic cancer cell lines. The isoform selectivity of these ligands for the Class I HDACs (HDAC1-3 and 8) and Class IIb HDACs (HDAC6 and HDAC10) together with QSAR studies of their correlation with the lipophilicity are presented. Of particular interest is the HDAC6 selectivity of the mercaptoacetamides.

Keywords

histone deacetylase inhibitors; biphenyl; phenylthiazole; isoform selectivity; pancreatic cancer

Introduction

The post-translational acetylation status of chromatin is determined by the competing activities of two classes of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). In general, HATs function to acetylate the epsilon amino group of conserved lysine residues within the N-terminal tails of histones, resulting in neutralization of the charges on the histones and a more open, transcriptionally active chromatin structure, while the HDACs function to deacetylate and promote transcriptional repression. A shift in the balance of acetylation on chromatin may result in changes in the regulation of patterns of gene expression. [1-4] Since many cancers are associated with aberrant transcriptional activity, and the HDACs can affect transcription factors and gene regulation, these enzymes have been identified as attractive targets for cancer therapy. Indeed, chemical inhibitors of HDACs have been shown to inhibit tumor cell growth and induce differentiation and cell death.[5] Several such inhibitory

agents, including suberoyanilide hydroxamic acid (SAHA, aka vorinostat) and depsipeptide (FR901228) have reached clinical trials,[6-8] and SAHA has been approved by the FDA for use in cutaneous T-cell lymphoma (CTCL). The HDAC inhibitors (HDACIs) also enhance the cytotoxic effects of both radiation and chemotherapeutic drugs.[9,10] Moreover, other studies support the possibility to use HDAC inhibitors in neurodegenerative diseases such as Parkinson's and Huntington's disease wherein they lead to the expression of certain neuroprotective proteins. While a number of different structural classes HDACIs have now been identified, the majority of these have not been tested for their selectivity against the individual HDAC isoforms of which there are now 11 that operate through zinc-dependent mechanisms. These include both the class I HDACs 1, 2, 3, and 8, class II that includes 4, 5, 6, 7, 9, and 10, and class IV that contains HDAC11.[11] In order to learn more about the role that the individual HDACs play in cell growth and/or differentiation, neuronal protection, and apoptosis, it is important to develop agents showing selectivity for individual isoforms or a small subset of these isoforms. While some rather limited degree of isoform selectivity has been shown by a few compounds,[12] this problem of identifying selective inhibitors is far from solved, and the problem is rather complicated by the functional interactions between different HDAC isoforms together with the formation of co-repressor complexes with other proteins that could possibly alter their interaction with various small molecule inhibitors.

The active site of class I, II and IV HDACs is found within a highly conserved catalytic domain containing a divalent zinc cation that is coordinated to both histidine and aspartate residues. Deacetylation of the HDAC substrates occurs through attack by a water molecule that is activated through interaction with this zinc cation coupled with deprotonation through a histidine-aspartate charge-relay system. Based upon what is currently known about the structure activity relationships of various HDAC inhibitors together with co-crystal structural information of the bacterial HDAC homologue HDLP[13] as well as human HDAC7 (PDB: 2PQO and 2PQP) and 8 (PDB: 1VKG, 1T67, 1T64, 1T69 and 2V5X)[14,15] in complex with certain known hydroxamate-based HDAC inhibitors, we have designed and synthesized certain hydroxamate-based HDACIs that present topologically unique end groups or CAPs. As the CAP region of the HDACIs is able to interact with the surface of the protein, in the region immediately outside of the catalytic gorge, it is able to serve as a recognition motif that may differentiate among the different HDAC isoforms. Similar research was exemplified by the identification of the putative HDAC6 selective tubacin from Schreiber's group by employing combinatorial synthesis and cell-based screening of a ~ 7000-compound library[16] [however, recent work suggests that its selectivity for HDAC6 versus 1, may only be 4-fold in enzyme assays].[17] On the other hand, our own work revealed that certain small molecule HDACIs bearing a mecaptoacetamide group as the Zinc Binding Group (ZBG) preferably inhibit HDAC6 over other HDACs.[18] Certain other types of HDACIs containing thiol[19] or benzamide-based ZBGs[20] have also been reported to show some level of isoform selectivity or class selectivity. However, strict head-to-head comparisons of the potency and selectivity of the non-hydroxamate based HDACIs over those containing a hydroxamate group as the ZBGs are relatively rare.

To pursue our plan of generating HDACIs containing topologically differentiated end groups, we have designed ligands that are comprised of a 2,4'-diaminobiphenyl scaffold in which the *para*-amino group bears an appendage that contains either a hydroxamate group or a mercaptoacetamide group that interacts with the catalytic zinc atom. The other amino group is used for the introduction of functionality that may discern among the various HDACs through a combination of steric or electronic effects. In particular, as presented in Scheme 1 and 2, we have prepared a series of diaminobiphenyls in which the *ortho*-amino group is coupled with one of the known amino acids. As all protein-protein interactions are governed by complementary amino acid interactions, we reasoned that this design strategy might best lead to reasonably active structures showing some degree of isoform selectivity. Five natural amino

acids, namely, glycine, phenylalanine, proline, tryptophan and tyrosine were explored in these studies and were selected based upon considerations of structural diversity.

Additionally, for comparison purposes, we also investigated the effect of replacing the biphenyl group by a phenylthiazole containing a substituent at either the 2- or the 3-position of the phenyl ring. This structural modification was explored based upon the realization that connectivity through the five-membered thiazole ring will locate the phenyl ring substituent closer to the HDAC protein surface. Moreover, we were inspired to investigate these particular analogs, as previously, some related phenylthiazoles were shown to provide very potent antiproliferative agents.[21] As will be seen below, in this series of compounds we found that certain bulk alkyl groups led to a substantial increased in inhibitory activity for HDAC6. Below we detail the procedures used to prepare these compounds, and then provide the biological results including cell-based assays, together with the preliminary QSAR study for the synthetic ligands.

Results and Discussion

Chemical Synthesis

Synthesis of the biphenyl hydroxamic acid series outlined in Scheme 1 started from 4'-nitrobiphenyl-2-ylamine (**1**) prepared from commercially available biphenyl-2-ylamine according to a known procedure.[22] The *ortho*-NH₂ substituent was selected for functionalization with various amino acids, as this position would best allow for possible surface interactions. The phenylalanine, tryptophan, and tyrosine-based hydroxamates **5b**, **5d** and **5e** were reported in our previous paper in comparison with certain mercaptoacetamides in neuroprotection assays carried out using cortical neurons from homocysteate (HCA) induced apoptosis.[18] Thus, 4'-nitrobiphenyl-2-ylamine (**1**) was coupled with the protected amino acids **2a-e** using POCl₃ in dry pyridine[23] to give corresponding amides **3a-e**. Concerning possible racemization of the amino acid in the peptide coupling step, we compared the optical purity of amide **3b** with its enantiomer **3g** prepared from BOC-*D*-Phe-OH by using of chiral HPLC. In agreement with a related literature[23] we found that no racemization had taken place in this amide forming reaction using POCl₃. Reduction of the nitro group was achieved by Pd (OH)₂ catalyzed hydrogenation or in case of the tyrosine intermediate **3e**, by using tin (II) chloride to avoid undesirable *O*-benzyl group cleavage. The resulting biphenylamines **4a-e** were coupled with 7-benzoyloxycarbonylheptanoic acid (**5**)[24] by PyBOP to afford the corresponding amides **6a-e**. Acid deprotection of the BOC group followed by hydrogenation led to the hydroxamates **7a-e**. The compounds containing an unsubstituted NH₂ group **7f** and the BOC protected amine group **7g** were also prepared in order to allow for appropriate comparisons with their amino acid substituted counterparts **7a-e**. Additionally, the analog without any *ortho*-substitution **7h** was prepared in order to better gauge the contribution that this substituent makes to HDAC inhibitory activity.[25]

The amino acid based biphenyl bearing mercaptoacetamides were prepared as shown in Scheme 2. The biphenylamines **4a-e** were coupled with 7-(2-tritylsulfanylacetyl)amino heptanoic acid (**8**)[26] by PyBOP, followed by one pot deprotection of both the trityl and Boc groups of **9a-d** with TFA/triethylsilane to afford the mercaptoacetamides **10a-d**. Removal of the benzyl group in the tyrosine intermediate **9e** using catalytic hydrogenation was sluggish, and extended reaction times led to cleavage of the thiol group to afford **11**.

The preparation of the *ortho*- and *meta*-amino substituted phenylthiazole-based HDACIs is outlined in Scheme 3 starting from commercially available 4-(3-nitrophenyl)thiazol-2-ylamine (**12a**) and 4-(2-nitrophenyl)thiazol-2-ylamine (**12b**). This chemistry proceeds in a relatively straightforward fashion, and as most of phenylthiazole-based intermediates are solid and easily purified by washing with appropriate solvents. Compound **16b** was chosen previously as one example of a hydroxamate to compare with the mercaptoacetamides described in our earlier

neuroprotection studies.¹⁷ In the present isoform selectivity study, we also prepared the non-substituted phenylthiazole **24** for use as control employing a similar synthetic protocol. The simple phenylthiazole ligand and some of its substituted counterparts were first reported by Abbott in 2004, and such compounds appear to act as relatively potent, pan-HDACs inhibitors. [12] The synthesis of the glycine bearing phenylthiazole analog is also outlined in Scheme 3. Thus, **14b** was coupled with BOC-Gly-OH using EEDQ, and then the ester **18** was hydrolyzed by LiOH to afford acid **19**. In this synthesis route, we chose the THP protected hydroxylamine as the precursor to the hydroxamate, and in the last step of the synthesis, both the THP and BOC groups were removed by treatment with TFA to afford **21**. In another attempt to prepare this hydroxamate using the mixed anhydride, we obtained the ethyl carbamate **23**.

Scheme 4 presents the synthesis of phenylthiazoles **25a**, **25b**, **27** and **29** imbued with an amide or urethane residue on the benzene ring in linkage with a bulkier alkyl group.

HDAC isoform inhibition assay

The putative HDACs described above were now screened both *in vitro* for enzyme inhibitory activity and then for their ability to block cancer cell growth. The inhibitory effects of compounds on histone deacetylase (HDAC) activity were determined using a fluorescence-based assay with electrophoretic separation of substrate and product carried out using a microfluidic system followed by quantitation of fluorescence intensity in the substrate and product peaks. The assays were performed using isolated HDAC isoforms that had been expressed as 6 × His-tagged fusion proteins in a baculovirus expression system in Sf9 cells. HDACs 1, 2, 3, 6, and 8 were expressed as full length fusion proteins. The HDAC10 fusion protein was expressed as a carboxy-terminal deletion of 38 amino acids (residues 632-669). HDAC3 was coexpressed with a fragment of the SMRT gene (residues 395-489) to generate enzymatically active protein. The data are presented as IC₅₀ values in Table 1 for the biphenyl HDACIs and in Table 2 for the phenylthiazole HDACIs. TSA was used as a positive control. The recently published inhibitory data for SAHA against a panel of recombinant HDACs are also presented for comparison.[27] As apparent from Table 1, the unsubstituted biphenyl hydroxamate **7h** shows marginal selectivity for inhibition of HDACs 3 and 6 over HDACs 1, 2 and 10, with all of these being in the nanomolar range; for HDAC8, the IC₅₀ was 1.87 μM. Introduction of an *ortho*-amino or substituted *ortho*-amino group [NH₂, BOCNH, glycine, or proline] as in **7g**, **7f**, **7a**, and **7c** resulted in a diminution of about 2-4 folds in inhibitory activity for the isoforms tested. The incorporation of the additional functional group thus appears not to play a role in the discrimination of the isoforms. In the case of the phenylalanine, tryptophan, and tyrosine derived ligands **7b**, **7d** and **7e**, their inhibitory activities against HDAC1 are almost same as that of **7h**; the only modest difference between these three ligands relative to **7h** is their decreased inhibitory activity for HDAC2 (3-5 folds). In general, all five of the amino acid bearing biphenyl hydroxamates are relatively potent HDAC inhibitors, however, they fail to show any real isoform discrimination.

Data for four amino acid bearing biphenyl mercaptoacetamides **10a-d** are shown in Table 1. Compared with their corresponding hydroxamates, these mercaptoacetamides preferentially inhibit HDAC6 over HDACs1, 2, and 10. The most selective mercaptoacetamide was the proline containing derivative **10c**, with an IC₅₀ value of 1.95 μM against HDAC1 and 0.2 μM against HDAC6. The inhibition pattern and activity range shown by these mercaptoacetamides against the different isoforms agree well with the data previously reported for such mercaptoacetamides from our laboratory.[18] Taken together, these data suggest that the mercaptoacetamide group represent a structurally unique type of ZBG that embodies some inherent selectivity for HDAC6.

The use of a phenylthiazole as the CAP group for HDAC inhibitors has previously been reported by Glaser et al.[28] using either an α-ketoamide or a hydroxamate as the ZBG. As is

readily apparent from Table 2, the phenylthiazole HDACIs are more potent inhibitors than the biphenyl HDACIs found in Table 1, with IC_{50} values for HDAC1 close to that shown by TSA. In comparison with the unsubstituted phenylthiazole **24**, the introduction of an amino group as in **17a** and **17b** or a glycineamide residue as in **21** caused little change in either activity or isoform selectivity. The nitro containing phenylthiazoles **16a** and **16b** are also reasonably potent, although the *ortho*-nitro compound **16a** is almost 10-fold less potent than the corresponding amine analog **17a**. The meta-substituted ethyl carbamate **23** was as potent as its amine analog **17b** against HDAC1 and HDAC2, but it showed a 3-fold improvement in its HDAC6 inhibitory activity. On further changing the ethyl carbamate in **23** to a *tert*-butyl carbamate as in **25b**, a further increase in HDAC6 inhibitory activity was found ($IC_{50} < 0.2$ nM), with no change in inhibitory activity towards either HDAC1 or HDAC2. Also, in comparison to the unprotected *ortho*-amino bearing ligand **17a**, introduction of a Boc protecting group as in **25a** leads to a > 15 -fold enhancement in the inhibitory activity towards HDAC6 with little change in inhibitory potency towards HDAC1 and HDAC2. Interestingly, replacement of the *tert*-butoxy group of **25b** by a cyclohexyl group as in **29**, leads to subnanomolar potency against both HDAC2 and HDAC3 ($IC_{50}s < 0.2$ nM, >200 -fold increase against HDAC2 and >20 -fold increase against HDAC3), while the IC_{50} for HDAC6 was still below 0.2 nM. On the other hand, the *ortho*-substituted *tert*-butyl carbamate **25a** showed a 2-fold decrease in activity toward HDAC1 and HDAC2, with similar inhibitory potency against HDAC6, as compared to the unprotected *ortho*-NH₂ ligand **17a**. Also, conversion of the BOC-protected ligand **25b** to the closely related pivaloyl derivative **27** results in a more than 10-fold decrease in HDAC6 inhibition and in only modest changes in the inhibition of the other isoforms, suggesting that the carbamate linkage and its extra oxygen atom can influence isoform(s) differentiation.

Antiproliferative Activity

Pancreatic cancer is the fourth leading cause of cancer death in the United States, and remains an incurable disease with a five-year survival of less than 5%. Increasing evidences indicate that signaling and transcriptional pathways are dysregulated in pancreatic cancer. Recently, SAHA had been tested against six pancreatic cancer cell lines and found to induce pancreatic cancer cell apoptosis, G2 cell cycle arrest and differentiation. Also, the combination of SAHA and DNA methylation inhibitor, 5-aza-2'-deoxycytidine, had an enhanced antiproliferative effect on pancreatic cancer cells.[29]

As a further measure of the activity of the present series of compounds, we examined their growth inhibiting effects against five pancreatic cancer cell lines using MTT assay. The preliminary antiproliferative results are outlined in Table 4, with SAHA being used as a reference point for comparison with our own compounds in this study. As apparent from these data, the unsubstituted biphenyl *o*-NH₂ hydroxamate **7g** is as potent as SAHA for inhibiting the growth of the BxPC-3, HupT3, Panc 04.03, and SU 86.86 pancreatic cancer cell lines, while the other three phenylalanine, proline, and tyrosine-bearing biphenyl hydroxamates **7b**, **7c**, and **7e** are less potent. However, in the case of the Mia Paca-2 cell line, all the biphenyl hydroxamates tested show potencies that are comparable or better than those of SAHA. On the other hand, the substituted phenylthiazole based inhibitors showed comparable or improved potencies compared to SAHA and the biphenyl ligands against all five pancreatic cancer cell lines. Among these ligands, the *meta*-amino substituted phenylthiazole **17b** gave the best IC_{50} value against the Mia Paca-2 cell line ($IC_{50} = 10$ nM), while its carbamate analog **23** provided the best overall inhibitory activity against all five pancreatic cancer cell lines.

QSAR Studies

In order to examine the SAR quantitatively, the compounds listed in Tables 1 and 2 were investigated using the classical QSAR (see Table 4). QSARs 1-5 (Table 5) were developed

from the 23 biphenyls or phenylthiazoles bearing hydroxamates or mercaptoacetamides against HDAC1, HDAC2, HDAC8, HDAC10, and HDAC6. The pIC_{50} values, the calculated log P values (ClogP), [30] and the indicator variables I-NHCOCH₂SH and I-Thiazole used in the correlations are listed in Table 4. The indicator variable I-NHCOCH₂SH takes the value of 1.0 for the mercaptoacetamides and 0.0 for all others. The indicator variable I-Thiazole takes the value of 1.0 for the phenylthiazoles and 0.0 for all others.

Eq. 1 shows that the majority of the variance in the inhibitory activity (expressed as pIC_{50}) of the inhibitors against HDAC1 can be explained with the three different classes of the compounds: biphenylhydroxamates, biphenylmercaptoacetamides, and phenylthiazoles. The negative coefficient of I-NHCOCH₂SH indicates that the biphenylmercaptoacetamides are 70 times (1.844 in log unit) less potent than and the phenylthiazoles are 9.6 times (0.983 in log unit) more potent than the biphenylhydroxamates. The squared correlation coefficient is excellent (0.920) and the root mean square error (RMSE) is reasonable (0.322). Figure 2a is a plot between the observed and the calculated pIC_{50} (HDAC1) values using eq. 1. Similar correlations were obtained against HDAC2 and HDAC10 (eq. 2 and eq. 4). Two compounds **10b**, **10d** have IC_{50} value of >30000. If one includes these with the value of 30,000, an essentially identical correlation is obtained with significantly improved statistics (eq. 2a). The correlation (eq. 3) against HDAC8 shows that the biphenylmercaptoacetamides are 2.9 times (−0.461 in log unit) less potent than both the phenylthiazoles and the biphenylhydroxamates. The lower squared correlation coefficient of eq. 3 is partly due to the narrow range of the pIC_{50} values among the compounds included. However, the small RMSE value (0.176) of eq. 3 shows the goodness of this correlation relative to all the other equations. Eq. 5 shows that the inhibitory activity of these compounds against HDAC6 is also influenced by the lipophilicity of the molecules in addition to the similar differences of the biphenylmercaptoacetamides and the phenylthiazoles observed in eqs. 1, 2, and 4. Figure 2b is a plot between the observed and the calculated pIC_{50} (HDAC6) values using eq. 5. Overall, the majority of the variance in pIC_{50} values of these compounds studied is explained by the three classes of compounds. The differences among the CAP groups influence the inhibitory activity only to a minor degree.

Equations 6 - 9 are the correlations describing the effects of the structural and physicochemical properties on the selectivity of HDAC6 against HDAC1, HDAC2, HDAC10, and HDAC8, respectively. Eq. 6a shows that the inhibitory potency of these molecules between HDAC6 and HDAC1 is highly correlated ($R^2 = 0.911$). Eq. 6 indicates that the lipophilicity of the molecules explains an additional 3% of the variance in the selectivity. Figure 2c shows the observed and the calculated pIC_{50} values for the selectivity of HDAC6 over HDAC1 using eq. 6. Similar results are obtained for the selectivity between HDAC6 and HDAC10 (eq. 8 and 8a). The R^2 for the correlation between HDAC6 and HDAC2 is 0.804 (eq. 7a). The selectivity toward HDAC6 over HDAC2 is accounted for by 1% improvement in R^2 with an indicator variable I-Thiazole for the phenylthiazoles (Compare eq. 7 with 7a). The selectivity between HDAC6 and HDAC8 is explained by 6% improvement in R^2 with the inclusion of the lipophilicity of the molecules (Compare eq. 9 with 9a) in the correlation. Eq. 9b shows that the phenylthiazoles described with the indicator variable I-Thiazole accounts for 42% of the selectivity of HDAC6 over HDAC8.

Four compounds were not included in some of the QSARs described in Table 5 partially because of the lack of a fixed IC_{50} value. The IC_{50} values of both **10b** and **10d** are > 30,000 nM (pIC_{50} value of < 4.52) against HDAC2 and the value of **10d** against HDAC10 was the same. The inhibitory activity of these compounds is the weakest. These compounds are predicted to have weak inhibitory activity. The calculated pIC_{50} values of these compounds from the corresponding QSAR are 4.85 against HDAC2 and 5.16 against HDAC10, which is the lowest calculated value among the compounds studied in the corresponding case. The

IC₅₀ value against HDAC2 of **29** is < 0.2 nM (pIC₅₀ value of > 9.70). This compound is predicted to be very potent. The calculated pIC₅₀ value of this compound is 7.42, which is the highest calculated value among the compounds studied. Therefore, both the 'actives' and 'inactives' not included in the QSARs are well predicted. The inhibitory activity of two compounds **25a** and **29** against HDAC6 is < 0.2 nM (pIC₅₀ value of > 9.70). The IC₅₀ value of 0.2 nM is used in the QSARs of HDAC6. The calculated pIC₅₀ values of these two compounds are 8.98 and 9.09, respectively, the highest potency among the compounds used.

The QSARs obtained for the various HDACs contained in this study suggest that their inhibitory activities on the different HDAC isoforms of HDAC are highly correlated. The QSARs also support the notion that the selectivity between HDAC6 and HDAC1 (as well as HDAC8 and HDAC10) can be increased with a minimum lipophilicity point of zero. Examination of the homology models of these HDACs (data not presented here) further support this observation, as the pertinent HDACs possess structurally similar binding pockets.

Conclusion

In summary, we have synthesized a series of structurally unique HDAC inhibitors in which the 2,4'-diaminobiphenyl group appropriately decorated with an amino acid residue serves as a potential isoform differentiating, surface recognition element. The surface recognition group is connected through the usual carbon linker to either a hydroxamate or a mercaptoacetamide group that chelates to the catalytic site zinc atom. Different amino acids as well as other structural motifs (e.g., carbohydrates) can be attached to the 2,4'-diaminobiphenyl moiety in order to investigate the possibility to achieve further levels of discrimination among the different HDAC isoforms. While the results obtained from this first generation of amino acid bearing HDACs reveal some modest degree of isoform selectivity over a panel of six HDAC isoforms, these compounds serve as relatively potent HDAC inhibitors, and are able to block the growth of five pancreatic cancer cell lines. The mercaptoacetamide bearing HDACs all show some preference for HDAC6 inhibition. Perhaps of greatest interest, the present work has led to the identification of two hydroxamates bearing *meta*-substituted phenylthiazole CAPs **25b** and **29** that exhibit picomolar IC₅₀ values in the *in vitro* HDAC6 inhibition studies; compound **29** also inhibits HDAC2 and HDAC3 with IC₅₀ values in the picomolar range. Moreover, several of these phenylthiazoles exhibit submicromolar to low nanomolar IC₅₀ values in the pancreatic cancer cell proliferation studies. It is our plan to construct a series of second generation inhibitors for isozyme studies using related scaffolds, but with the putative surface recognition element located on the aryl ring that is linked to the ZBG. Further modeling studies are underway to better understand the activity of these phenylthiazoles relative to their biphenyl counterparts. Also, cell based experiments will be conducted in order to obtain some measure of the possible isoform and tissue selectivity of these new inhibitors under more biologically relevant conditions, in which the HDACs are able to engage in complex formation with other proteins, including transcription factors as well as other HDACs. Lastly, we call attention to the fact that in other studies reported recently by us, certain mercaptoacetamides do show useful levels of HDAC6 selectivity.[18]

Experimental Section

Synthesis

¹H NMR and ¹³C NMR spectra were recorded on Bruker spectrometer at 300/400 MHz and 75/100 MHz respectively with TMS as an internal standard. Standard abbreviation indicating multiplicity was used as follows: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintuplet, m = multiplet and br = broad. HRMS experiment was performed on Q-TOF-2TM (Micromass). TLC was performed with Merck 250-mm 60F₂₅₄ silica gel plates. Preparative TLC was performed with Analtech 1000-mm silica gel GF plates. Column chromatography

was performed using Merck silica gel (40-60 mesh). HPLC was carried out on an ACE AQ columns (100 × 4.6 mm and 250 × 10 mm), with detection at 254 nm on a Shimadzu SPD-10A VP detector; flow rate = 2.0-3.5 mL·min⁻¹; from 10% acetonitrile in water to 100% acetonitrile with 0.05% TFA. Optical rotations were obtained on a Rudolph-Autopol® IV Polarimeter.

Typical procedure for octanedioic acid hydroxyamides **7a**, **7c**, **7d**, **7f** and **7g**

The following method represents a typical procedure for the synthesis of the octanedioic acid hydroxyamide-based ligands. The synthesis of **7b**, **7d** and **7e** were described in our previous paper.[18]

(4'-Nitrobiphenyl-2-yl)carbamic acid tert-butyl ester (**3f**)

A mixture of 4'-nitrobiphenyl-2-ylamine (**1**) (0.857 g, 4.0 mmol) and di-*tert*-butyl dicarbonate (0.870 g, 4.0 mmol) in toluene was heated to 100 °C overnight, and then an additional amount of di-*tert*-butyl dicarbonate (0.175 g, 0.8 mmol) was added. The mixture was kept at 100 °C for another 4 h, and the solvent was then evaporated in vacuo. The solid residue was washed with hexanes/EtOAc 4:1, filtered, and dried to yield (4'-nitrobiphenyl-2-yl)carbamic acid tert-butyl ester **3f** (1.0 g, 79%). ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.23 (s, 9H), 7.31-7.41 (m, 4H), 7.65 (d, *J* = 8.7 Hz, 2H), 7.54 (d, *J* = 8.7 Hz, 2H).

Octanedioic acid {2'-[2-amino-3-(1H-indol-3-yl)propionylamino]-biphenyl-4-yl}amide hydroxyamide (**7d**)

To a stirred solution of Boc-*L*-Trp-OH (1.67 g, 5.4 mmol) and 4'-nitrobiphenyl-2-ylamine (1.18 g, 5.4 mmol) in dry pyridine (20 mL), POCl₃ (0.84 g, 5.4 mmol) was added dropwise at -15 °C. The reaction was kept at the same temperature for 1 h, then concentrated to remove part of the pyridine. The residue was dissolved in EtOAc, washed thoroughly with saturated NH₄Cl solution and brine, the organic phase was separated, dried over Na₂SO₄, filtered and concentrated. The crude material was purified by flash chromatography (acetone/hexane, 1:1) to give compound **3d** (1.6 g, 58%). ¹H NMR (CDCl₃, 400 Hz): δ = 1.36 (s, 9H), 3.17 (dd, *J* = 7.6 and 14.4 Hz, 1H), 3.39 (dd, *J* = 4.0 and 14.4 Hz, 1H), 4.39-4.46 (m, 1H), 4.95-5.12 (m, 1H), 6.99 (d, *J* = 8.7 Hz, 1H), 7.00 (s, 1H), 7.18-7.10 (m, 2H), 7.20-7.27 (m, 2H), 7.36-7.45 (m, 2H), 7.53 (s, 1H), 7.61 (d, *J* = 7.9 Hz, 1H), 7.90 (d, *J* = 8.4 Hz, 2H), 8.22-8.27 (m, 2H). ¹³C NMR (CDCl₃, 75 MHz): δ = 28.5, 56.5, 60.8, 110.4, 111.7, 119.2, 120.5, 122.3, 123.1, 123.8, 124.3, 125.3, 127.5, 130.0, 130.1, 130.2, 130.8, 134.3, 136.6, 144.9, 147.5, 170.4.

A suspension of compound **3d** (1.80 g, 3.5 mmol) and Pd(OH)₂/C (20 wt. %, 0.5 g) in a mixture of methanol (10 mL) and CH₂Cl₂ (10 mL) was stirred under hydrogen atmosphere for 4h at room temperature. The catalyst was removed by filtration through a pad of Celite and the solvent was evaporated to give a residue which was purified by flash chromatography (ethyl acetate/hexane 1:1 then 2:1) to give compound **4d** (1.40 g, 83%). ¹H NMR (CDCl₃, 300 Hz): δ = 1.38 (s, 9H), 3.12-3.28 (m, 1H), 3.30-3.45 (m, 1H), 4.46 (br s, 1H), 5.08 (br s, 1H), 6.35 (br s, 2H), 6.61 (br s, 2H), 6.95 (s, 1H), 7.08-7.19 (m, 4H), 7.22 (t, *J* = 7.2 Hz, 1H), 7.27-7.40 (m, 3H), 7.62 (d, *J* = 7.3 Hz, 1H), 7.77 (br s, 1H), 8.35 (br s, 2H). ¹³C NMR (CD₃OD, 75 MHz): δ = 28.6, 56.7, 80.4, 111.7, 115.9, 119.2, 120.1, 121.0, 122.5, 123.8, 124.7, 125.0, 128.1, 130.2, 130.2, 132.6, 134.7, 136.6, 145.8, 155.6, 170.1.

To a stirred solution of 7-benzyloxycarbonylheptanoic acid (**5**) (0.13 g, 0.46 mmol) in dry DMF (5 mL) DIPEA (0.120 g, 0.92 mmol) was added, and the mixture was stirred for 10 min at room temperature. Then PyBOP (0.480 g, 0.92 mmol) and biphenyl amine **4d** (0.220 g, 0.46 mmol) were added sequentially and stirring was continued over night. The reaction mixture was diluted with diethyl ether, washed with water, saturated NaHCO₃ solution, saturated NH₄Cl solution, and brine, and dried over Na₂SO₄, filtered, and then concentrated. The crude material was purified by flash chromatography (acetone/hexane, 1:1) to give compound **6d**

(0.233 g, 70%). ^1H NMR (CDCl_3 , 300 Hz): δ = 1.30-1.50 (m, 13H), 1.60-1.85 (m, 4H), 2.06 (br s, 2H), 2.37 (t, J = 7.1 Hz, 2H), 2.94-3.20 (m, 1H), 3.25-3.48 (m, 1H), 4.37 (br s, 1H), 4.92 (s, 2H), 5.21 (br s, 1H), 6.73 (br s, 2H), 6.84 (br s, 1H), 7.18-7.00 (m, 4H), 7.26-7.45 (m, 9H), 7.45-7.60 (m, 2H), 7.68 (br s, 1H), 8.30 (br s, 1H), 8.51 (br s, 1H), 8.83 (br s, 1H).

To a solution of compound **6d** (0.046 mg, 0.063 mmol) in CH_2Cl_2 (5 mL) at 0 °C, TFA (2 mL) was added. After 2 h the reaction mixture was diluted with diethyl ether, washed with saturated aqueous NaHCO_3 and brine, dried over Na_2SO_4 , then filtered, and concentrated. The crude material was purified by flash chromatography (methanol/ CH_2Cl_2 , 10:1) to give amine (0.020 g, 51%). ^1H NMR (CDCl_3 , 300 Hz): δ = 1.32-1.78 (m, 8H), 2.04 (br s, 2H), 2.33 (br t, 2H), 3.00 (dd, J = 7.9 and 14.3 Hz, 1H), 3.31 (dd, J = 4.4 and 14.5 Hz, 1H), 3.71 (dd, J = 4.2 and 7.5 Hz, 1H), 4.90 (br s, 2H), 6.84 (s, 1H), 7.04- 7.22 (m, 6H), 7.32- 7.42 (m, 7H), 7.48 (d, J = 7.9 Hz, 2H), 7.61 (d, J = 7.8 Hz, 1H), 7.80 (br s, 1H), 8.35 (d, J = 8.1 Hz, 1H), 8.48-8.62 (br d, 1H), 9.49 (s, 1H). ^{13}C NMR (CDCl_3 , 75 MHz) δ = 24.5, 24.7, 25.9, 26.0, 28.0, 29.3, 29.8, 29.9, 31.4, 32.4, 36.8, 46.6, 50.4, 55.3, 65.4, 77.7, 110.3, 111.0, 118.4, 119.0, 119.6, 120.5, 121.0, 121.6, 123.0, 123.9, 124.1, 127.0, 127.8, 128.2, 128.3, 128.8, 129.4, 129.6, 132.0, 133.5, 134.3, 134.8, 136.0, 137.1, 170.6, 171.5, 172.8.

A suspension of amine (0.031 g, 0.049 mmol) and $\text{Pd}(\text{OH})_2/\text{C}$ (20 wt. %, 0.010 g) in methanol was stirred under a hydrogen atmosphere at room temperature for 4 h. The catalyst was removed by filtration through a pad of Celite and the residue was thoroughly washed with MeOH. The solvent was evaporated and the residue was crystallized from methanol/ether, 5:95 to give hydroxamate **7d** (0.008 g, 30%). $[\alpha]_{\text{D}}^{24}$ = 11.5 (c = 0.27, CH_3OH). ^1H NMR (CD_3OD , 300 MHz): δ = 1.30-1.78 (m, 8H), 2.10 (d, J = 7.0 Hz, 2H), 2.37 (d, J = 7.0 Hz, 2H), 3.02-3.15 (m, 1H), 3.25-3.35 (m, 1H), 3.96-4.05 (m, 1H), 6.96-7.08 (m, 1H), 7.09-7.22 (m, 4H), 7.23-7.48 (m, 5H), 7.52-7.67 (m, 3H), 7.74 (d, J = 7.7 Hz, 1H). ^{13}C NMR ($\text{DMSO}-d_6$, 75 MHz) δ = 24.8, 24.9, 26.9, 28.0, 28.1, 31.9, 36.0, 53.5, 99.5, 106.1, 110.9, 114.7, 117.4, 118.6, 119.8, 121.2, 123.8, 125.2, 126.1, 126.4, 127.2, 128.7, 129.8, 132.7, 133.8, 136.0, 136.4, 137.5, 167.5, 171.3, 173.1. ESI-HRMS calculated for $[\text{C}_{31}\text{H}_{35}\text{N}_5\text{O}_4 + \text{H}]^+$: 542.2761; found: 542.2762. HPLC purity: 95%.

(2S)-[1-(4'-Nitrobiphenyl-2-ylcarbamoyl)-2-phenylethyl]carbamic acid *tert*-butyl ester (**3b**)

Compound **3b** (yield 47%) was prepared from BOC-*L*-Phe-OH according to the methodology described for the preparation of compound **3d**. The enantiomeric purity was determined on a Chiralpak AD column 10 $\times$ 250 mm, using hexane/2-propanol (70:30) as the mobile phase with a flow rate of 4mL/min. Detection was performed by use of a UV spectrometer Shimadzu SPD-10A VP at 254 nm, t_{R} = 7.4 min. $[\alpha]_{\text{D}}^{24}$ (>99% ee) = -3.2 (c = 0.16, CH_3OH). ^1H NMR (CDCl_3 , 400 MHz): δ = 1.33 (s, 9H), 3.11 (d, J = 6.8 Hz, 2H), 4.30-4.32 (m, 1H), 4.79 (br s, 1H), 7.18-7.32 (m, 9H), 7.42-7.46 (m, 1H), 7.62 (s, 1H), 8.21 (d, J = 8.8 Hz, 3H). ^{13}C NMR (CDCl_3 , 100 MHz): δ = 28.1, 37.9, 56.7, 80.6, 122.3, 124.0, 125.2, 125.8, 127.2, 128.8, 129.3, 129.6, 129.8, 130.0, 130.8, 133.8, 144.7, 147.2, 169.4.

(2R)-[1-(4'-Nitrobiphenyl-2-ylcarbamoyl)-2-phenylethyl]carbamic acid *tert*-butyl ester (**3g**)

Compound **3g** (yield 27%) was prepared from BOC-*D*-Phe-OH according to the methodology described for the preparation of compound **3d**. Enantiomeric purity was determined on a Chiralpak AD column 10 $\times$ 250 mm, using hexane/2-propanol (70:30) as the mobile phase with a flow rate 4mL/min. Detection was performed by UV spectrometer Shimadzu SPD-10A VP at 254 nm, t_{R} = 9.3 min. $[\alpha]_{\text{D}}^{24}$ (>99% ee) = +3.3 (c = 0.31, CH_3OH). ^1H NMR (CDCl_3 , 400 MHz): δ = 1.33 (s, 9H), 3.11 (d, J = 6.4 Hz, 2H), 4.30-4.32 (m, 1H), 4.79 (br s, 1H), 7.18-7.32 (m, 9H), 7.44 (t, J = 6.8 Hz, 1H), 7.62 (s, 1H), 8.21 (d, J = 8.8 Hz, 3H). ^{13}C NMR (CDCl_3 , 100 MHz): δ = 28.1, 37.9, 122.3, 124.0, 125.2, 125.8, 127.2, 128.8, 129.3, 129.6, 129.8, 130.0, 130.8, 133.8, 144.7, 147.2, 169.4.

Octanedioic acid [2'-(2-aminoacetyl-amino)biphenyl-4-yl]amide hydroxyamide (7a)

Compound **7a** was prepared from BOC-Gly-OH according to the methodology described for the preparation of compound **7d**. ^1H NMR (DMSO- d_6 , 400 MHz): δ = 1.37 (m, 4H), 1.48 (m, 2H), 1.57 (m, 2H), 1.93 (t, J = 7.2 Hz, 2H), 2.30 (t, J = 7.2 Hz, 2H), 3.43 (m, 2H), 3.62 (br s, 2H), 4.34 (t, J = 4.9 Hz, 1H), 7.32 (m, 5H), 7.50 (d, J = 7.5 Hz, 1H), 7.67 (d, J = 8.5 Hz, 2H), 8.65 (s, 1H), 9.99 (s, 1H), 10.34 (s, 1H). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 25.4, 25.5, 28.8, 30.8, 32.6, 34.8, 36.8, 119.4, 125.3, 126.8, 128.0, 128.4, 129.5, 130.8, 133.2, 133.9, 136.2, 139.1, 139.6, 166.0, 169.5, 171.8. ESI-HRMS calculated for $[\text{C}_{22}\text{H}_{28}\text{N}_4\text{O}_4 + \text{H}]^+$: 413.2189; found: 413.2182. HPLC purity: 96%.

Octanedioic acid hydroxyamide {2'-[(pyrrolidine-2-carbonyl)-amino]biphenyl-4-yl}amide (7c)

Compound **7c** was prepared from BOC-*L*-Pro-OH according to the methodology described for the preparation of compound **7d**. $[\alpha]_{\text{D}}^{24} = -38.0$ (c = 1, CH_3OH). ^1H NMR (DMSO- d_6 , 400 MHz): δ = 1.09 (m, 4H), 1.48-1.58 (m, 4H), 1.82-1.94 (m, 5H), 2.19 (m, 1H), 2.30 (m, 3H), 3.15 (m, 2H), 4.17 (m, 1H), 7.17-7.66 (m, 8H), 8.66 (br s, 1H), 9.95 (br s, 1H), 10.00 (br s, 1H), 10.35 (br s, 1H). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 23.9, 25.4, 28.8, 29.6, 32.6, 36.8, 46.1, 59.9, 119.3, 125.7, 128.1, 128.6, 129.3, 129.5, 130.7, 133.3, 133.9, 139.2, 169.5, 171.7. ESI-HRMS calculated for $[\text{C}_{25}\text{H}_{32}\text{N}_4\text{O}_4 + \text{H}]^+$: 453.2502; found: 453.2494. HPLC purity: 98%.

Octanedioic acid (2'-amino-biphenyl-4-yl)amide hydroxyamide (7f)

Compound **7f** was prepared from **3f** according to the methodology described for the preparation of compound **7d**. ^1H NMR (DMSO- d_6 , 300 MHz): δ = 1.28 (br s, 4H), 1.49-1.59 (m, 4H), 1.94 (t, J = 6.0 Hz, 2H), 2.30 (t, J = 6.0 Hz, 2H), 4.72 (br s, 2H), 6.61 (t, J = 6.0 Hz, 1H), 6.72 (d, J = 6.0 Hz, 1H), 6.95 (d, J = 6.0 Hz, 1H), 7.01 (t, J = 6.0 Hz, 1H), 7.32 (d, J = 9.0 Hz, 2H), 7.65 (d, J = 9.0 Hz, 2H), 8.66 (s, 1H), 9.93 (s, 1H), 10.33 (s, 1H); ^{13}C NMR (100 MHz, DMSO- d_6): δ = 25.4, 25.5, 28.8, 32.6, 36.8, 115.5, 117.1, 119.7, 125.9, 128.3, 129.2, 130.3, 134.6, 138.4, 145.4, 169.5, 171.6; ESI-HRMS calculated for $[\text{C}_{20}\text{H}_{25}\text{N}_3\text{O}_3 + \text{H}]^+$: 356.1968; found: 356.1962. HPLC purity: 96%.

[4'-(7-Hydroxycarbamoyl-heptanoylamino)biphenyl-2-yl] carbamic acid *tert*-butyl ester (7g)

Compound **7g** was prepared from **3f** according to the methodology described for the preparation of compound **7d**, by omitting the use of TFA to remove the BOC protecting group of **6f**, and **7g** was purified by preparative HPLC. ^1H NMR (400 MHz, CD_3OD): δ = 1.35-1.45 (m, 13H), 1.65 (t, J = 6.8 Hz, 2H), 1.73 (t, J = 7.6 Hz, 2H), 2.11 (t, J = 7.2 Hz, 2H), 2.40 (t, J = 7.6 Hz, 2H), 7.20-7.24 (m, 1H), 7.27-7.30 (m, 1H), 7.31-7.35 (m, 3H), 7.55 (d, J = 7.2 Hz, 1H), 7.64 (d, J = 8.4 Hz, 2H); ^{13}C NMR (100 MHz, CD_3OD): δ = 25.1, 25.2, 27.1, 28.4, 36.4, 79.5, 119.8, 124.9, 125.8, 127.4, 129.0, 129.9, 134.7, 134.8, 137.8, 154.5, 173.2; ESI-HRMS calculated for $[\text{C}_{25}\text{H}_{33}\text{N}_3\text{O}_5 + \text{H}]^+$: 456.2493; found: 456.2491. HPLC purity: 96%.

Typical procedure for mercaptoacetamide-based ligand 10a-d

The following method represents a typical procedure for the synthesis of the 6-mercaptoacetyl-amino hexanoic acid amide-based ligands.

6-(2-Mercapto-acetyl-amino)-hexanoic acid {2'-[2-amino-3-(1H-indol-3-yl)propionyl-amino]biphenyl-4-yl}amide (10d)

To a stirred solution of 6-(2-tritylsulfanylacetyl-amino)hexanoic acid (**8**) (0.218 g, 0.48 mmol) in dry DMF, DIPEA (0.126 g, 0.97 mmol) was added, and the mixture was stirred for 10 min at room temperature. Then PyBOP (0.508 g, 0.97 mmol) and biphenyl amine **4d** (0.230 g, 0.48 mmol) were added, and stirring was continued overnight. The reaction mixture was diluted

with diethyl ether, washed consecutively with cold water, saturated NaHCO₃ solution, saturated NH₄Cl solution, and brine, and dried over Na₂SO₄, filtered, and concentrated. The crude material was purified by flash chromatography (acetone/hexane, 1:1) to give compound **9d** (0.224 g, 51%). ¹H NMR (CD₃OD, 300 MHz) δ = 1.30-1.50 (m, 13H), 1.69 (t, J = 6.7 Hz, 2H), 2.28-2.40 (m, 2H), 2.90-3.02 (m, 2H), 3.05-3.20 (m, 3H), 3.24-3.45 (m, 1H), 4.38 (br s, 1H), 5.21 (br s, 1H), 6.11 (t, J = 5.4 Hz, 1H), 6.68-6.82 (m, 3H), 6.94-7.18 (m, 4H), 7.20-7.48 (m, 22H), 7.53 (d, J = 7.7 Hz, 1H), 7.69 (br s, 1H), 8.15 (s, 1H), 8.27 (d, J = 6.9 Hz, 1H), 9.08 (s, 1H). ¹³C NMR (CDCl₃, 75 MHz) δ = 14.6, 19.3, 21.4, 25.4, 26.7, 28.6, 29.3, 36.4, 37.5, 39.9, 60.8, 68.2, 80.4, 109.9, 111.9, 119.0, 119.8, 121.6, 121.6, 122.3, 123.7, 124.9, 127.5, 127.7, 128.5, 129.8, 130.3, 132.6, 133.6, 134.6, 136.7, 138.0, 144.3, 155.6, 168.6, 170.6, 171.6, 172.2.

To a solution of compound **9d** (0.070 g, 0.077 mmol) in CH₂Cl₂ at 0 °C, TFA (1 mL) was added. The resulting yellow solution was treated dropwise with triethylsilane until the color disappeared. The mixture was then stirred for 2 h, and the solvent was evaporated. The residue was dissolved in EtOAc and washed consecutively with a saturated NaHCO₃ solution and brine, and the organic phase was dried over Na₂SO₄, filtered, and concentrated. The crude material was purified by flash chromatography (methanol/CH₂Cl₂, 1:10) to give compound **10d** (0.026 mg, 60%). $[\alpha]_D^{24}$ = 11.7 (c = 0.16, CH₃OH). ¹H NMR (CD₃OD, 400 Hz): δ = 1.50-1.48 (m, 2H), 1.53-1.65 (m, 2H), 1.68-1.78 (m, 2H), 2.40 (t, J = 7.4 Hz, 2H), 3.03 (dd, J = 7.1 and 14.3 Hz, 1H), 3.13 (s, 2H), 3.15-3.28 (m, 3H), 3.69 (dd, J = 6.9 and 12.4 Hz, 1H), 6.97 (t, J = 7.1 Hz, 1H), 7.02-7.13 (m, 4H), 7.18-7.28 (m, 2H), 7.30-7.40 (m, 2H), 7.49 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H). ¹³C NMR (CD₃OD, 75 MHz): δ = 25.4, 26.4, 26.5, 29.0, 29.0, 30.4, 36.7, 39.5, 39.7, 42.0, 55.9, 109.9, 111.3, 118.5, 118.9, 120.3, 121.5, 123.8, 123.3, 125.3, 127.7, 127.9, 129.6, 130.2, 134.5, 137.2, 138.3, 170.1, 173.4. ESI-HRMS calculated for [C₃₁H₃₆N₅O₃S + H]⁺: 558.2539; found: 558.2533. HPLC purity: 96%.

6-(2-Mercaptoacetyl-amino)hexanoic acid [2'-(2-aminoacetyl-amino)biphenyl-4-yl]amide (**10a**)

Compound **10a** was prepared according to the methodology described for the preparation of compound **10d**. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.32 (m, 2H), 1.45 (m, 2H), 1.61 (m, 2H), 2.32 (t, J = 7.3 Hz, 2H), 3.10 (m, 2H), 3.35 (m, 4H), 3.47 (s, 2H), 7.23-7.37 (m, 7H), 7.70 (d, J = 8.5 Hz, 2H), 7.91 (d, J = 7.9 Hz, 1H), 8.11 (t, J = 5.3 Hz, 1H), 9.77 (s, 1H), 10.00 (s, 1H). ¹³C NMR (DMSO-*d*₆, 75 MHz): δ = 24.9, 26.1, 28.8, 36.4, 38.2, 42.0, 42.9, 119.1, 123.5, 125.1, 127.7, 129.3, 130.3, 132.6, 133.8, 134.2, 138.8, 167.6, 168.7, 171.3. ESI-HRMS calculated for [C₂₂H₂₈N₄O₃S + H]⁺: 429.1960; found: 429.1953. HPLC purity: 97%.

6-(2-Mercaptoacetyl-amino)hexanoic acid [2'-(2-amino-3-phenyl-propionyl-amino)biphenyl-4-yl]amide (**10b**)

Compound **10b** was prepared according to the methodology described for the preparation of compound **10d**. $[\alpha]_D^{24}$ = -22.0 (c = 0.5, CH₃OH). ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.07 (t, J = 7.0 Hz, 1H), 1.17 (t, J = 7.0 Hz, 1H), 1.31 (m, 2H), 1.44 (m, 2H), 1.59 (m, 2H), 2.31 (m, 2H), 2.85 (m, 1H), 3.07 (m, 4H), 3.48 (br s, 2H), 3.90 (m, 1H), 7.14-7.37 (m, 10 H), 7.64 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 7.7 Hz, 1H), 8.11 (br s, 1H), 9.81 (br s, 1H), 9.98 (s, 1H). ¹³C NMR (DMSO-*d*₆, 75 MHz): δ = 25.2, 26.5, 29.2, 36.8, 38.2, 42.4, 46.1, 55.0, 119.5, 124.9, 125.9, 127.2, 127.8, 128.8, 129.5, 129.8, 130.6, 132.9, 134.2, 135.0, 136.2, 139.1, 168.0, 169.3, 171.7. ESI-HRMS calculated for [C₂₉H₃₄N₄O₃S]⁺: 518.2351; found: 518.2339. HPLC purity: 96%.

Pyrrolidine-2-carboxylic acid {4'-[6-(2-mercaptoacetyl-amino)-hexanoylamino]biphenyl-2-yl} amide (10c)

Compound **10c** was prepared according to the methodology described for the preparation of compound **10d**. $[\alpha]_D^{24} = 7.1$ ($c = 0.07$, CH₃OH). ¹H NMR (DMSO-*d*₆, 400 MHz): $\delta = 1.25$ -1.70 (m, 8H), 1.78 (m, 1H), 1.96 (m, 1H), 2.23-2.35 (m, 4H), 2.55 (m, 1H), 3.08 (m, 3H), 3.59 (m, 1H), 7.13-7.34 (m, 7H), 7.70 (d, $J = 11.2$ Hz, 2H), 8.11 (m, 1H), 8.28 (d, $J = 10.8$ Hz, 1H), 10.00 (br s, 1H), 10.13 (br s, 1H). ¹³C NMR (DMSO-*d*₆, 75 MHz): $\delta = 25.2$, 26.2, 26.5, 29.2, 30.7, 36.8, 42.4, 46.8, 60.9, 119.5, 120.4, 124.1, 128.6, 129.3, 129.8, 130.4, 132.0, 132.6, 135.4, 139.2, 168.0, 171.7, 173.5. ESI-HRMS calculated for [C₂₅H₃₂N₄O₃S]⁺: 468.2195; found: 468.2186. HPLC purity: 98%.

(2-(4-Benzoyloxyphenyl)-1-{4'-[6-(2-tritylsulfanylacetyl-amino) hexanoylamino]biphenyl-2-yl}carbamoyl)ethyl)carbamic acid *tert*-butyl ester (9e)

Compound **9e** (yield 76%) was prepared according to the methodology described for the preparation of compound **9d**. ¹H NMR (CD₃OD, 300 MHz): $\delta = 1.20$ -1.45 (m, 13H), 1.71 (t, $J = 6.6$ Hz, 2H), 2.32 (d, $J = 7.2$ Hz, 2H), 2.90-3.10 (m, 4H), 3.12 (s, 2H), 4.26 (br s, 1H), 4.90-5.10 (m, 3H), 6.07 (br s, 1H), 6.90 (d, $J = 8.2$ Hz, 2H), 6.95-7.11 (m, 4H), 7.12-7.45 (m, 24H), 7.58 (d, $J = 7.9$ Hz, 2H), 7.76 (br s, 1H), 7.93 (br s, 1H), 8.35 (d, $J = 7.6$ Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz): $\delta = 14.6$, 21.4, 25.3, 26.6, 28.5, 29.3, 36.3, 37.7, 37.9, 39.8, 60.8, 68.3, 70.3, 80.5, 115.5, 120.4, 121.3, 124.9, 127.5, 127.8, 128.3, 128.6, 128.9, 129.4, 129.8, 129.9, 130.5, 130.7, 132.2, 133.3, 134.5, 137.3, 144.3, 138.4, 158.2, 168.4, 169.8, 171.5, 171.6.

6-(2-Mercapto-acetyl-amino)hexanoic acid {2'-[2-amino-3-(4-benzyloxyphenyl) propionyl-amino]biphenyl-4-yl}amide (10e)

Compound **10e** (yield 45%) was prepared according to the methodology described for the preparation of compound **10d**. ¹H NMR (CD₃OD, 300 MHz): $\delta = 1.65$ -1.35 (m, 4H), 1.77 (t, $J = 7.1$ Hz, 2H), 2.38 (t, $J = 8.1$ Hz, 2H), 2.74 (dd, $J = 13.9$ and 8.6 Hz, 1H), 3.20 (s, 2H), 3.29 (dd, $J = 12.7$ and 6.3 Hz, 2H), 3.60 (dd, $J = 8.3$ and 3.8 Hz, 1H), 5.10-4.95 (m, 1H), 6.98-6.82 (m, 3H), 7.05-7.45 (m, 14H), 7.59 (d, $J = 8.0$ Hz, 2H), 7.92 (s, 1H), 8.38 (d, $J = 8.0$ Hz, 1H), 9.57 (s, 1H).

6-Acetyl-amino-hexanoic acid {2'-[2-amino-3-(4-hydroxyphenyl)-propionyl-amino]biphenyl-4-yl}amide (11)

A suspension of compound **10e** (0.035 g, 0.056 mmol) and Pd(OH)₂/C (20 wt. %, 0.010 g) in methanol (5 mL) was stirred under a hydrogen atmosphere at room temperature for 10 h. The catalyst was removed by filtration through a pad of Celite and the residue was thoroughly washed with MeOH. The solvent was evaporated, and the crude material was dissolved in EtOAc, and the solvent was removed by rotary evaporation. The crude solid was purified by flash chromatography (methanol/dichloromethane, 1:10) to give compound **11** (0.007 g, 24%). ¹H NMR (CD₃OD, 300 MHz): $\delta = 1.50$ -1.45 (m, 2H), 1.65-1.50 (m, 2H), 1.85-1.70 (m, 2H), 1.93 (s, 3H), 2.41 (t, $J = 7.1$ Hz, 2H), 2.75 (dd, $J = 13.2$ and 7.2 Hz, 1H), 2.93 (dd, $J = 13.3$ and 6.1 Hz, 1H), 3.19 (t, $J = 6.9$ Hz, 2H), 3.57 (t, $J = 6.0$ Hz, 1H), 6.74 (d, $J = 8.2$ Hz, 2H), 7.02 (d, $J = 8.2$ Hz, 2H), 7.40-7.13 (m, 5H), 7.60 (d, $J = 8.3$ Hz, 2H), 7.96 (d, $J = 7.9$ Hz, 1H); ¹³C NMR (CD₃OD, 75 MHz): $\delta = 21.5$, 25.5, 26.5, 29.1, 36.8, 39.2, 39.7, 56.8, 105.7, 115.4, 120.3, 123.4, 125.4, 127.9, 128.1, 129.6, 130.3, 130.5, 134.4, 138.4, 156.4, 172.2, 173.5, 174.3.

Typical procedure for 4-phenylthiazolyl amides of octanedioic acid hydroxyamide 16a, 16b, 17a and 17b

The synthesis of ligand **16b** was described in our previous paper.[18]

Octanedioic acid [4-(3-nitrophenyl)thiazol-2-yl]amide methyl ester (13b)

A stirred solution of 4-(3-nitrophenyl)thiazol-2-ylamine **13a** (2.21 g, 10 mmol) and suberic acid monomethyl ester (1.88 g, 10 mmol) in dry pyridine (20 mL) was cooled to -15°C and POCl_3 (1.2 mL, 13 mmol) was added dropwise over 30 min. After stirring for another 1 h at the same temperature, the reaction mixture was diluted with EtOAc and washed thoroughly with saturated aqueous KHSO_4 and brine, dried over Na_2SO_4 , filtered and concentrated. The crude material was washed with EtOAc to give compound **13b** (2.40 g, 62%). ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): δ = 1.30 (br s, 4H), 1.53 (t, J = 6.8 Hz, 2H), 1.61 (t, J = 6.5 Hz, 2H), 2.30 (t, J = 7.3 Hz, 2H), 2.46 (t, J = 7.5 Hz, 2H), 7.74 (t, J = 7.9 Hz, 1H), 3.58 (3H, s), 7.93 (s, 1H), 8.18 (d, J = 7.8 Hz, 1H), 8.35 (d, J = 7.1 Hz, 1H), 8.74 (d, J = 1.4 Hz, 1H), 12.3 (s, 1H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ = 24.6, 24.8, 28.5, 28.6, 33.6, 35.2, 51.6, 110.8, 120.5, 122.7, 130.8, 132.1, 136.2, 146.7, 148.7, 158.8, 172.1.

Octanedioic acid [4-(2-nitrophenyl)thiazol-2-yl]amide methyl ester (13a)

Compound **13a** was prepared according to the methodology described for the preparation of compound **13b**, the crude solid was washed with methanol to get the pure **13a** (yield 48 %). ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): δ = 1.28 (br s, 4H), 1.52 (t, J = 6.1 Hz, 2H), 1.57 (t, J = 6.6 Hz, 2H), 2.29 (t, J = 7.4 Hz, 2H), 2.44 (t, J = 7.3 Hz, 2H), 3.58 (s, 3H), 7.52 (s, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.89 (d, J = 8.6 Hz, 1H), 12.1 (s, 1H). ^{13}C NMR ($\text{DMSO}-d_6$, 100 MHz): δ = 24.6, 24.8, 28.5, 28.6, 33.6, 35.1, 51.6, 112.2, 124.4, 128.8, 129.6, 131.2, 132.9, 145.3, 149.0, 158.3, 172.1, 173.7.

Octanedioic acid [4-(3-aminophenyl)thiazol-2-yl]amide methyl ester (14b)

A suspension of compound **13b** (0.391 g, 1 mmol) and Pd/C (10 wt.%, 50 mg) in EtOH and AcOH (20 mL + 1 mL) was reacted under hydrogen atmosphere at 50°C for 2 h. The catalyst was removed by filtration through a pad of *celite*. The solvent was evaporated. The crude material was dissolved in EtOAc, washed consecutively with NaHCO_3 solution and brine, dried over Na_2SO_4 , filtered and concentrated. The crude solid was purified by flash chromatography (EtOAc/hexane, 2:1) to give compound **14b** (0.261 g, 72%). ^1H NMR (CDCl_3 , 300 MHz): δ = 1.08-1.22 (m, 4H), 1.61-1.45 (m, 4H), 2.06 (dd, J = 7.3 and 4.7 Hz, 2H), 2.28 (t, J = 7.4 Hz, 2H), 3.69 (s, 3H), 6.70-6.66 (m, 1H), 7.10 (s, 1H), 7.16 (br s, 1H), 7.20 (s, 1H), 7.22 (s, 1H), 11.2 (s, 1H). ^{13}C NMR (CDCl_3 , 75 MHz): δ = 21.4, 25.00, 25.09, 29.01, 29.07, 34.3, 36.1, 51.9, 108.1, 113.0, 115.3, 116.9, 130.2, 135.7, 147.3, 150.1, 159.6, 171.8, 174.6.

Octanedioic acid [4-(2-aminophenyl)thiazol-2-yl]amide methyl ester (14a)

Compound **14a** (yield 81%) was prepared according to the methodology described for the preparation of compound **14b**. ^1H NMR (CDCl_3 , 400 MHz): δ = 1.19-1.30 (m, 4H), 1.55-1.62 (m, 4H), 2.12 (t, J = 7.5 Hz, 2H), 2.30 (t, J = 7.6 Hz, 2H), 3.61 (s, 3H), 4.73 (br s, 1H), 6.76 (m, 2H), 7.07 (s, 1H), 7.17 (t, J = 7.0 Hz, 1H), 7.47 (d, J = 7.0 Hz, 1H), 10.38 (br s, 1H). ^{13}C NMR (CDCl_3 , 100 MHz): δ = 24.5, 24.6, 28.5, 28.6, 33.9, 35.6, 51.5, 108.9, 116.8, 118.4, 119.0, 129.1, 129.4, 158.3, 171.0, 174.1.

Octanedioic acid hydroxyamide [4-(3-aminophenyl)thiazol-2-yl] amide (17b)

To a solution of hydroxylamine hydrochloride (0.958 g, 13.8 mmol) in MeOH, KOH (0.772 g, 13.8 mmol) was added at 40°C for 10 min. The reaction mixture was cooled to 0°C and filtered. Compound **14b** (0.250 g, 0.69 mmol) was added to the filtrate followed by KOH (50 mg, 0.89 mmol) at room temperature for 30 min. The reaction mixture was extracted with EtOAc, and organic layer was washed with saturated NH_4Cl aqueous solution and brine, dried over Na_2SO_4 , filtered and concentrated. The crude solid was purified by preparative HPLC to give compound **17b** (0.110 g, 44 %). ^1H NMR (CD_3OD , 300 MHz): δ = 1.35-1.50 (m, 4H),

1.65 (t, $J = 7.0$ Hz, 2H), 1.74 (t, $J = 7.0$ Hz, 2H), 2.11 (t, $J = 7.2$ Hz, 2H), 2.51 (t, $J = 7.2$ Hz, 2H), 7.29 (dd, $J = 7.8$ and 1.2 Hz, 1H), 7.51 (s, 1H), 7.55 (t, $J = 7.8$ Hz, 1H), 7.90 (s, 1H), 7.98 (d, $J = 7.8$ Hz, 1H). ^{13}C NMR (CD_3OD , 100 MHz): $\delta = 24.3, 24.7, 27.9, 28.0, 34.6, 108.5, 119.2, 120.8, 125.1, 129.7, 136.3, 147.4, 158.0, 172.1$. ESI-HRMS calculated for $[\text{C}_{17}\text{H}_{22}\text{N}_4\text{O}_3\text{S} + \text{H}]^+$: 363.1485; found: 363.1482. HPLC purity: 97%

Octanedioic acid hydroxyamide [4-(2-aminophenyl)thiazol-2-yl] amide (17a)

Compound **17a** (yield 50%) was prepared according to the methodology described for the preparation of compound **17b**. ^1H NMR (CD_3OD , 400 MHz): $\delta = 1.35\text{--}1.50$ (m, 4H), 1.66 (m, 2H), 1.77 (m, 2H), 2.12 (t, $J = 7.3$ Hz, 2H), 2.55 (t, $J = 7.3$ Hz, 2H), 7.35 (d, $J = 7.7$ Hz, 1H), 7.43 (m, 2H), 7.63 (s, 1H), 7.94 (d, $J = 7.6$ Hz, 1H). ^{13}C NMR (CD_3OD , 100 MHz): $\delta = 24.3, 24.7, 27.9, 28.0, 31.8, 34.7, 110.3, 122.7, 125.3, 126.7, 128.0, 128.7, 145.8, 171.13, 172.0$. ESI-HRMS calculated for $[\text{C}_{17}\text{H}_{22}\text{N}_4\text{O}_3\text{S} + \text{H}]^+$: 363.1485; found: 363.1485. HPLC purity: 97%

Octanedioic acid [4-(3-nitrophenyl)thiazol-2-yl]amide (15b)

To a solution of compound **13b** (0.391 g, 1.0 mmol) in a mixture of MeOH (10 mL) and water (10 mL) was added LiOH·H₂O (0.839 g, 20.0 mmol), and the mixture was stirred at room temperature for 3 h. Then the reaction mixture was acidified with 1N HCl dropwise to pH 5 and extracted with EtOAc. The organic layer was washed consecutively with water and brine, dried over Na₂SO₄, filtered and then concentrated. The solvent was evaporated to give compound **15b** (0.322 g, 86%). ^1H NMR ($\text{DMSO-}d_6$, 300 MHz): $\delta = 1.18\text{--}1.30$ (m, 4H), 1.49 (t, $J = 6.3$ Hz, 2H), 1.60 (br s, 2H), 2.19 (t, $J = 5.7$ Hz, 2H), 2.45 (t, $J = 6.5$ Hz, 2H), 7.72 (t, $J = 8.0$ Hz, 1H), 7.91 (s, 1H), 8.16 (dd, $J = 7.9$ and 2.8 Hz, 1H), 8.33 (d, $J = 7.6$ Hz, 1H), 8.72 (s, 1H), 12.3 (s, 1H). ^{13}C NMR ($\text{DMSO-}d_6$, 75 MHz): $\delta = 25.1, 25.3, 29.1, 31.2, 34.4, 35.7, 111.2, 120.9, 123.0, 131.2, 132.5, 136.6, 147.1, 149.1, 159.2, 172.5, 175.3$.

Octanedioic acid hydroxyamide [4-(3-nitrophenyl)thiazol-2-yl]amide (16b)

To a solution of compound **15b** (0.100 g, 0.26 mmol) in dry THF was added Et₃N (0.18 mL, 1.3 mmol) under nitrogen, and the solution was stirred for 5 min. The solution was cooled to -15°C and stirred for another 5 min. Then, *iso*-butyl chloroformate (67 μL , 0.52 mmol) was added dropwise, and the mixture was stirred for 15 min. The solid was filtered. The filtrate was cooled to 0°C , and a 50% aqueous solution of NH₂OH (1 mL) was added over 10 min. The reaction mixture was diluted with EtOAc, washed with saturated aqueous NH₄Cl and brine, dried over Na₂SO₄, filtered, and concentrated. The solvent was removed by rotary evaporation. The crude solid was purified by preparative HPLC to give compound **16b** (0.027 g, 26%). ^1H NMR ($\text{DMSO-}d_6$, 300 MHz): $\delta = 1.35\text{--}1.50$ (m, 4H), 1.50 (t, $J = 6.1$ Hz, 2H), 1.60 (br s, 2H), 1.94 (t, $J = 7.2$ Hz, 2H), 2.45 (t, $J = 7.2$ Hz, 2H), 7.73 (t, $J = 7.9$ Hz, 1H), 7.91 (s, 1H), 8.17 (dd, $J = 8.1$ and 1.5 Hz, 1H), 8.34 (d, $J = 7.7$ Hz, 1H), 8.67 (br s, 1H), 8.72 (s, 1H), 10.3 (s, 1H), 12.3 (s, 1H); ^{13}C NMR ($\text{DMSO-}d_6$, 100 MHz): $\delta = 24.9, 25.4, 28.7, 32.6, 35.3, 110.8, 120.4, 122.7, 130.8, 132.1, 136.2, 146.7, 148.7, 158.8, 169.5, 172.1$. ESI-HRMS calculated for $[\text{C}_{17}\text{H}_{20}\text{N}_4\text{O}_5\text{S} + \text{H}]^+$: 393.1227; found: 393.1227. HPLC purity: 96%.

Octanedioic acid hydroxyamide [4-(2-nitrophenyl)thiazol-2-yl] amide (16a)

Compound **16a** was prepared from **13a** according to the methodology described for the preparation of compound **16b**. ^1H NMR ($\text{DMSO-}d_6$, 400 MHz): $\delta = 1.26$ (m, 4H), 1.48 (m, 2H), 1.58 (m, 2H), 1.94 (t, $J = 7.04$ Hz, 2H), 2.44 (t, $J = 7.04$ Hz, 2H), 7.52 (s, 1H), 7.61 (t, $J = 7.4$ Hz, 1H), 7.71–7.79 (m, 2H), 7.89 (d, $J = 7.8$ Hz, 1H), 10.34 (s, 1H), 12.15 (s, 1H). ^{13}C NMR ($\text{DMSO-}d_6$, 100 MHz): $\delta = 25.0, 25.4, 28.7, 32.7, 35.2, 112.2, 124.4, 128.8, 129.7, 131.3, 133.0, 145.3, 149.0, 158.4, 169.5, 172.2$. ESI-HRMS calculated for $[\text{C}_{17}\text{H}_{20}\text{N}_4\text{O}_5\text{S} + \text{H}]^+$: 393.1227; found: 393.1227. HPLC purity: 97%.

Octanedioic acid [4-[3-(2-aminoacetyl-amino)phenyl]thiazol-2-yl]amide hydroxylamide (21)

To a solution of compound **14b** (0.100 g, 0.27 mmol) and BOC-Gly-OH (0.242 mg, 1.35 mmol) in dry DMF (10 mL) at room temperature was added EEDQ (0.333 g, 1.35 mmol), and the mixture was stirred at 40 °C overnight. The reaction mixture was diluted with ethyl acetate, and washed with water, saturated NaHCO₃ solution, saturated NH₄Cl solution, and brine, and dried over Na₂SO₄. The solvent was evaporated and the crude product was purified by flash chromatography (ethyl acetate/hexane 1:2, then ethyl acetate/hexane 1:1) to give compound **18** (0.087 g, 61%). ¹H NMR(CDCl₃, 400 MHz): δ = 1.33 (br s, 4H), 1.45 (s, 9H), 1.62 (t, J = 6.8 Hz, 2H), 1.71 (br s, 2H), 2.31 (t, J = 7.4 Hz, 2H), 2.43 (br s, 2H), 3.68 (s, 3H), 4.04 (br s, 2H), 7.08 (s, 1H), 7.33 (t, J = 7.7 Hz, 1H), 7.44 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 7.2 Hz, 1H), 7.91 (br s, 1H), 8.60 (br s, 1H). ¹³C NMR (CDCl₃, 100 MHz): δ = 24.6, 24.7, 28.2, 28.7, 33.9, 35.9, 51.5, 108.1, 117.7, 122.1, 129.4, 138.0, 148.6, 159.4, 171.7, 174.2.

To a solution of compound **18** (0.06 g, 0.11 mmol) in a mixture of MeOH (10 mL) and water (10 mL) was added LiOH·H₂O (0.097 g, 2.2 mmol), and the mixture was stirred at room temperature for 1 h. The reaction mixture was acidified with 1N HCl dropwise to pH 5 and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na₂SO₄, and then filtered. The solvent was evaporated to give compound **19** (0.047 g, 81%). ¹H NMR(CDCl₃, 400 MHz): δ = 1.39 (br s, 4H), 1.46 (s, 9H), 1.65 (t, J = 6.7 Hz, 2H), 1.75 (br s, 2H), 2.35 (t, J = 7.3 Hz, 2H), 2.50 (t, J = 7.4 Hz, 2H), 4.01 (br s, 2H), 7.02 (s, 1H), 7.34 (d, J = 7.6 Hz, 1H), 7.38 (br s, 1H), 7.53 (br s, 1H), 7.84 (br s, 1H), 8.78 (br s, 1H). ¹³C NMR (CDCl₃, 100 MHz): δ = 24.4, 24.7, 28.2, 28.5, 33.9, 35.8, 108.3, 117.9, 119.8, 122.4, 129.4, 134.3, 137.9, 148.5, 160.3, 171.9, 177.0.

To a stirred solution of compound **19** (0.045 g, 0.089 mmol) and THPONH₂ (0.021 mg, 0.178 mmol) in dry DCM (10 mL) at room temperature, HOBt (0.025 g, 0.178 mmol) and EDCI (0.034 g, 0.178 mmol) were added sequentially and stirring was continued overnight. The reaction mixture was diluted with ethyl acetate, washed with water, saturated NaHCO₃ solution, saturated NH₄Cl solution, and brine, and dried over Na₂SO₄, filtered, and concentrated. The crude material was purified by flash chromatography (ethyl acetate/hexane 1:1, then ethyl acetate) to give compound **20** (0.047 g, 89%). ¹H NMR(DMSO-*d*₆, 400 MHz): δ = 1.27 (br s, 4H), 1.41 (s, 9H), 1.45-1.70 (m, 10H), 1.98 (t, J = 6.5 Hz, 2H), 2.45 ((t, J = 7.1 Hz, 2H), 3.45-3.52 (m, 1H), 3.73 (s, 2H), 3.88-3.95 (s, 1H), 4.80 (s, 1H), 7.30-7.40 (m, 2H), 7.52 (s, 1H), 7.57 (d, J = 7.1 Hz, 1H), 8.29 (s, 1H), 9.98 (s, 1H), 10.90 (s, 1H), 12.28 (s, 1H). ¹³C NMR (DMSO-*d*₆, 100 MHz): δ = 18.7, 25.0, 25.1, 25.2, 28.2, 28.6, 32.5, 35.2, 44.1, 61.7, 78.4, 101.2, 108.4, 117.2, 118.9, 121.0, 129.4, 135.2, 139.7, 149.1, 156.4, 158.3, 168.6, 169.4, 172.0.

To a solution of compound **20** (0.040 mg, 0.066 mmol) in CH₂Cl₂ (5 mL) at 0 °C, TFA (2 mL) was added. After 10 min, the reaction mixture was concentrated in vacuo. The crude material was purified by preparative HPLC to give compound **21** (0.016 g, 67%). ¹H NMR(CD₃OD, 400 MHz): δ = 1.42 (br s, 4H), 1.65 (t, J = 6.8 Hz, 2H), 1.75 (t, J = 7.0 Hz, 2H), 2.11 (t, J = 7.4 Hz, 2H), 2.50 (t, J = 7.3 Hz, 2H), 3.89 (s, 2H), 7.36 (s, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 7.7 Hz, 1H), 8.18 (s, 1H). ¹³C NMR (CD₃OD, 100 MHz): δ = 24.3, 24.7, 27.9, 28.0, 31.8, 34.6, 40.3, 107.2, 116.6, 118.4, 121.5, 128.4, 135.1, 137.7, 148.8, 157.6, 163.6, 172.0. ESI-HRMS calculated for [C₁₉H₂₅N₅O₄S₁ + H]⁺: 420.1700; found: 420.1697. HPLC purity: 95%.

Octanedioic acid [4-(3-aminophenyl)thiazol-2-yl]amide (22)

Compound **22** (yield 80%) was prepared according to the methodology described for the preparation of compound **15b**. ¹H NMR (CDCl₃, 300 MHz): δ = 1.35-1.50 (m, 4H), 1.69 (t, J = 6.7 Hz, 2H), 1.78 (br s, 2H), 2.40 (t, J = 7.1 Hz, 2H), 2.49 (t, J = 7.3 Hz, 2H), 6.69 (d, J =

7.8 Hz, 1H), 6.99 (s, 2H), 7.07 (d, $J = 8.2$ Hz, 1H), 7.21 (t, $J = 7.7$ Hz, 1H). ^{13}C NMR (CDCl_3 , 75 MHz): $\delta = 24.9, 25.5, 28.9, 29.1, 34.4, 130.2, 36.7, 108.1, 113.5, 115.6, 117.3, 135.0, 147.1, 149.7, 160.8, 172.2, 179.6$.

Octanedioic acid hydroxyamide [4-(3-urethanylphenyl)thiazol-2-yl]amide (23)

Compound **23** was prepared according to the methodology described for the preparation of compound **16b**, by substituting compound **15b** with compound **22** and using ethyl chloroformate. The crude material was purified by preparative HPLC to give the desired product (0.130 g, 12%). ^1H NMR ($\text{DMSO}-d_6$, 300 MHz): $\delta = 1.23\text{--}1.27$ (m, 5H), 1.48 (m, 2H), 1.59 (m, 2H), 1.93 (t, $J = 6.8$ Hz, 2H), 2.44 (t, $J = 7.3$ Hz, 2H), 4.13 (q, $J = 7.1$ Hz, 2H), 7.31 (br s, 2H), 7.47 (br s, 2H), 8.11 (s, 1H), 9.68 (s, 1H), 10.3 (s, 1H), 12.2 (s, 1H); ^{13}C NMR ($\text{DMSO}-d_6$, 100 MHz): $\delta = 14.9, 25.0, 25.4, 28.7, 32.6, 35.2, 60.6, 108.3, 116.0, 118.2, 120.3, 129.4, 135.3, 140.0, 149.2, 154.0, 158.3, 169.5, 172.0$. ESI-HRMS calculated for $[\text{C}_{20}\text{H}_{26}\text{N}_4\text{O}_5\text{S} + \text{H}]^+$: 435.1696; found: 435.1694. HPLC purity: 96%.

7-[4-(2-tert-Butoxycarbonylamino-phenyl)-thiazol-2-ylcarbamoyl]-heptanoic acid methyl ester (24a)

A mixture of **14a** (0.1 g, 0.27 mmol) and di-*tert*-butyl dicarbonate (0.6 g, 2.7 mmol) in THF was refluxed overnight. The solvent was then evaporated in vacuo and the residue was dissolved in ethyl acetate, washed with saturated NaHCO_3 solution and brine, dried over Na_2SO_4 , filtered and concentrated. The crude material was purified by flash chromatography (ethyl acetate/hexane 1:3) to give compound **24a** (0.087 g, 69%). ^1H NMR (CDCl_3 , 400 MHz): $\delta = 1.05\text{--}1.11$ (m, 2H), 1.16-1.24 (m, 2H), 1.34 (s, 9H), 1.50-1.60 (m, 4H), 1.98 (t, $J = 7.6$ Hz, 2H), 2.30 (t, $J = 7.6$ Hz, 2H), 3.67 (s, 3H), 7.07 (t, $J = 8.0$ Hz, 1H), 7.12 (s, 1H), 7.35 (t, $J = 8.0$ Hz, 1H), 7.52 (d, $J = 8.0$ Hz, 1H), 8.32 (br s, 1H), 8.98 (br s, 1H), 11.03 (br s, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): $\delta = 24.3, 24.6, 28.4, 28.6, 28.7, 33.9, 35.5, 51.4, 110.5, 121.6, 122.6, 129.2, 129.5, 136.3, 148.0, 152.7, 159.6, 171.3, 174.1$.

{2-[2-(7-Hydroxycarbamoylheptanoylamino)thiazol-4-yl] phenyl} carbamic acid *tert*-butyl ester (25a)

Compound **25a** (yield 57%) was prepared according to the methodology described for the preparation of compound **17b**. ^1H NMR (CD_3OD , 400 MHz): $\delta = 1.41$ (br s, 4H), 1.52 (s, 9H), 1.65 (t, $J = 6.8$ Hz, 2H), 1.74 (t, $J = 6.8$ Hz, 2H), 2.10 (t, $J = 7.2$ Hz, 2H), 2.51 (t, $J = 7.2$ Hz, 2H), 7.08 (t, $J = 7.6$ Hz, 1H), 7.28-7.32 (m, 2H), 7.62 (d, $J = 8.0$ Hz, 1H), 8.00 (d, $J = 8.0$ Hz, 1H); ^{13}C NMR (CD_3OD , 100 MHz): $\delta = 24.3, 24.7, 26.8, 27.9, 28.0, 31.8, 34.6, 79.6, 109.4, 120.1, 122.3, 123.0, 127.8, 128.0, 135.4, 147.9, 153.2, 157.8, 171.1, 172.0$. ESI-HRMS calculated for $[\text{C}_{22}\text{H}_{30}\text{N}_4\text{O}_5\text{S}_1 + \text{H}]^+$: 463.2009; found: 463.2003. HPLC purity: 96%.

{3-[2-(7-Hydroxycarbamoylheptanoylamino)thiazol-4-yl]phenyl} carbamic acid *tert*-butyl ester (25b)

Compound **25b** (yield 64%) was prepared according to the methodology described for the preparation of compound **17b**. ^1H NMR (CD_3OD , 400 MHz): $\delta = 1.40$ (br s, 4H), 1.62 (s, 9H), 1.64 (t, $J = 6.8$ Hz, 2H), 1.73 (t, $J = 6.4$ Hz, 2H), 2.10 (t, $J = 7.6$ Hz, 2H), 2.48 (t, $J = 7.6$ Hz, 2H), 7.28-7.29 (m, 2H), 7.33 (s, 1H), 7.54 (t, $J = 2.8$ Hz, 1H), 8.03 (s, 1H); ^{13}C NMR (CD_3OD , 100 MHz): $\delta = 24.7, 25.1, 27.2, 28.3, 32.2, 35.0, 79.0, 107.2, 116.1, 117.8, 120.3, 125.8, 128.5, 135.1, 139.4, 149.6, 153.9, 171.5, 172.4$. ESI-HRMS calculated for $[\text{C}_{22}\text{H}_{30}\text{N}_4\text{O}_5\text{S}_1 + \text{H}]^+$: 463.2009; found: 463.2003. HPLC purity: 96%.

7-{4-[3-(2,2-Dimethylpropionylamino)phenyl]thiazol-2-yl carbamoyl}heptanoic acid methyl ester (26)

A mixture of **14b** (0.120 g, 0.33 mmol) and trimethylacetic anhydride (0.618 g, 3.3 mmol) in dry THF was refluxed overnight. The solvent was then evaporated and the residue was dissolved in ethyl acetate, then washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and concentrated. The crude material was purified by flash chromatography (ethyl acetate/hexane 1:3) to give compound **26** (0.117 g, 79%). ¹H NMR (CDCl₃, 400 MHz): δ = 1.06-1.14 (m, 2H), 1.17-1.23 (m, 2H), 1.34 (s, 9H), 1.53-1.55 (m, 4H), 2.16 (t, J = 8.0 Hz, 2H), 2.28 (t, J = 8.0 Hz, 2H), 3.68 (s, 3H), 7.16 (s, 1H), 7.34 (t, J = 8.0 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.74 (s, 1H), 8.17 (s, 1H), 10.95 (s, 1H); ¹³C NMR (CDCl₃, 100 MHz): δ = 24.6, 24.7, 27.5, 28.6, 33.8, 35.8, 39.6, 51.5, 108.2, 117.9, 119.6, 121.8, 129.2, 149.1, 158.9, 171.5, 174.3, 176.9.

Octanedioic acid {4-[3-(2,2-dimethylpropionylamino)phenyl] thiazol-2-yl}amide hydroxyamide (27)

Compound **27** (yield 42%) was prepared according to the methodology described for the preparation of compound **17b**. ¹H NMR (CD₃OD, 400 MHz): δ = 1.32 (s, 9H), 1.41 (br s, 4H), 1.64 (t, J = 6.8 Hz, 2H), 1.74 (t, J = 6.4 Hz, 2H), 2.11 (t, J = 7.2 Hz, 2H), 2.50 (t, J = 7.2 Hz, 2H), 7.32-7.36 (m, 2H), 7.44 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 8.11 (s, 1H); ¹³C NMR (CD₃OD, 100 MHz): δ = 24.7, 25.1, 26.3, 28.3, 32.2, 35.0, 39.0, 107.3, 119.0, 120.7, 121.7, 125.8, 128.4, 135.0, 138.6, 149.4, 157.9, 172.4, 178.5. ESI-HRMS calculated for [C₂₂H₃₀N₄O₄S₁ + H]⁺: 447.2060; found: 447.2052. HPLC purity: 96%.

7-{4-[3-(Cyclohexanecarbonylamino)phenyl]thiazol-2-yl-carbamoyl}heptanoic acid methyl ester (28)

A mixture of **14b** (0.100 g, 0.27 mmol) and cyclohexanecarbonyl chloride (0.45 g, 2.7 mmol) in dry THF was refluxed overnight. The solvent was then evaporated and the residue was dissolved in ethyl acetate, washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and concentrated. The crude material was purified by flash chromatography (ethyl acetate/hexane 1:3) to give compound **28** (0.082 g, 61%). ¹H NMR (CDCl₃, 400 MHz): δ = 1.05-1.40 (m, 7H), 1.50-1.60 (m, 6H), 1.65-1.70 (m, 1H), 1.78-1.82 (m, 2H), 1.93-1.96 (m, 2H), 2.13 (t, J = 7.6 Hz, 2H), 2.27 (t, J = 7.6 Hz, 2H), 3.68 (s, 3H), 3.97 (t, J = 8.0 Hz, 1H), 5.63-5.65 (m, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.08 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 8.10 (s, 1H), 8.16 (s, 1H), 11.06 (br s, 1H); ¹³C NMR (CDCl₃, 100 MHz): δ = 23.8, 24.6, 25.6, 28.6, 28.7, 29.1, 29.5, 33.9, 35.7, 46.3, 51.5, 67.6, 107.8, 108.1, 117.8, 119.4, 121.6, 129.2, 134.9, 138.8, 159.0, 171.6, 174.4, 175.2.

Octanedioic acid {4-[3-(cyclohexanecarbonylamino)phenyl]-thiazol-2-yl}amide hydroxyamide (29)

Compound **29** (yield 45%) was prepared according to the methodology described for the preparation of compound **17b**. ¹H NMR (400 MHz, CD₃OD): δ = 1.27-1.40 (m, 8H), 1.51-1.63 (m, 4H), 1.73-1.75 (m, 2H), 1.83-1.91 (m, 4H), 2.17 (br s, 2H), 2.37-2.42 (m, 1H), 2.49 (t, J = 7.2 Hz, 2H), 7.31-7.34 (m, 2H), 7.45 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 8.14 (s, 1H). ¹³C NMR (100 MHz, CD₃OD): δ = 24.7, 25.1, 25.3, 25.4, 28.3, 29.2, 35.0, 45.7, 117.6, 119.3, 121.3, 128.5, 135.1, 138.9, 172.4, 176.3. MS ESI-HRMS calculated for [C₂₄H₃₂N₄O₄S₁ + H]⁺: 473.2217; found: 473.2207. HPLC purity: 96%.

HDACs Inhibition Assay

Purified HDACs were incubated with 1 μ M carboxyfluorescein (FAM)-labeled acetylated peptide substrate and test compound for 17 hours at 25 °C in HDAC assay buffer containing 100 mM HEPES (pH 7.5), 25 mM KCl, 0.1% BSA and 0.01% Triton X-100. Reactions were

terminated by the addition of buffer containing 0.078% SDS for a final SDS concentration of 0.05%. Substrate and product were separated electrophoretically using a Caliper LabChip 3000 system with blue laser excitation and green fluorescence detection (CCD2). The fluorescence intensity in the substrate and product peaks was determined using the Well Analyzer software on the Caliper system. The reactions were performed in duplicate for each sample. IC₅₀ values were automatically calculated using the IDBS XLFit version 4.2.1 plug-in for Microsoft Excel and the XLFit 4 Parameter Logistic Model (Sigmoidal Dose-response Model): $((A + ((B-A)/(1 + ((C/x)^D))))$, where x is compound concentration, A is the estimated minimum and B is the estimated maximum of % inhibition, C is the inflection point and D is the Hill slope of the sigmoidal curve. The standard errors of the IC₅₀s were automatically calculated using the IDBS XLFit version 4.2.1 plug-in for Microsoft Excel and the formula `xf4_FitResultStdError()`.

Cytotoxicity Assays

The pancreatic cancer cell lines BxPc-3, HupT3, MiaPaCa-2, Panc 04.03, and SU86.86 were obtained from ATCC (Rockville, MD) and were grown in medium (DMEM or RPMI) containing 10% fetal calf serum and *L*-glutamine. Pancreatic cancer cells were plated out in duplicate into 6-wells of a 96-well microtiter plate at $2.5-4 \times 10^3$ cells per well. Four-hours post plating, individual wells were treated with diluent (DMSO) or varying concentrations of SAHA or the indicated HDACIs from a concentration of 1 nM to 50 μ M. Cytotoxicity was measured at time '0' and 72 h post treatment using the colorimetric MTS assay according to the manufacturer's suggestions (Promega, Madison, WI). The IC₅₀s were calculated using XLfit (IDBS Limited, Guildford, UK).

Acknowledgement

We are indebted to Dr. Rong He for assisting in the preparation of the manuscript. This work was supported in part by gift funds from an anonymous donor and by the Mayo Foundation and the Pancreatic Cancer SPORE P50 CA10270.

References

1. Grunstein M. *Nature* 1997;389:349–352. [PubMed: 9311776]
2. Wolffe AP, Guschin D. J. *Struct. Biol* 2000;129:102–122. [PubMed: 10806063]
3. Kurdistani SK, Grunstein M. *Nat. Rev. Mol. Cell Biol* 2003;4:276–284. [PubMed: 12671650]
4. Struhl K, Moqtaderi Z. *Cell* 1998;94:1–4. [PubMed: 9674419]
5. Marks PA, Richon VM, Rifkind RA. *J. Natl. Cancer Inst* 2000;92:1210–1216. [PubMed: 10922406]
6. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. *Clin. Cancer Res* 2003;9:3578–3588. [PubMed: 14506144]
7. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC. *Clin. Cancer Res* 2001;7:3047–3055. [PubMed: 11595694]
8. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. *Biochem. Pharmacol* 2002;64:1079–1090. [PubMed: 12234611]
9. Marks PA, Richon VM, Miller T, Kelly WK. *Adv. Cancer Res* 2004;91:137–168. [PubMed: 15327890]
10. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. *Nat. Rev. Cancer* 2001;1:194–202. [PubMed: 11902574]
11. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M. *J. Pharmacol. Exp. Ther* 2003;307:720–728. [PubMed: 12975486]
12. Glaser KB, Li J, Pease LJ, Staver MJ, Marcotte PA, Guo J, Frey RR, Garland RB, Heyman HR, Wada CK, Vasudevan A, Michaelides MR, Davidsen SK, Curtin ML. *Biochem. Biophys. Res. Commun* 2004;325:683–690. [PubMed: 15541343]
13. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. *Nature* 1999;401:188–193. [PubMed: 10490031]

14. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkuhler C, Di Marco S. *Proc. Natl. Acad. Sci. USA* 2004;101:15064–15069. [PubMed: 15477595]
15. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW. *Structure (Camb)* 2004;12:1325–1334. [PubMed: 15242608]
16. Sternson SM, Wong JC, Grozinger CM, Schreiber SL. *Org. Lett* 2001;3:4239–4242. [PubMed: 11784187]
17. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G. *J. Med. Chem* 2005;48:3344–3353. [PubMed: 15857140]
18. Kozikowski AP, Chen Y, Gaysin A, Chen B, D'Annibale MA, Suto CM, Langley BC. *J. Med. Chem* 2007;50:3054–3061. [PubMed: 17539623]
19. Suzuki T, Kouketsu A, Itoh Y, Hisakawa S, Maeda S, Yoshida M, Nakagawa H, Miyata N. *J. Med. Chem* 2006;49:4809–4812. [PubMed: 16884291]
20. Siliphaivanh P, Harrington P, Witter DJ, Otte K, Tempest P, Kattar S, Kral AM, Fleming JC, Deshmukh SV, Harsch A, Secrist PJ, Miller TA. *Bioorg. Med. Chem. Lett* 2007;17:4619–4624. [PubMed: 17555962]
21. Curtin M, Glaser K. *Curr. Med. Chem* 2003;10:2373–2392. [PubMed: 14529480]
22. Mendenhall GD, Smith DL. *Org. Synth* 1966;46:85–89.
23. Quelever G, Burlet S, Garino C, Pietrancosta N, Laras Y, Kraus JL. *J. Comb. Chem* 2004;6:695–698. [PubMed: 15360202]
24. Wittich S, Scherf H, Xie C, Brosch G, Loidl P, Gerhauser C, Jung M. *J. Med. Chem* 2002;45:3296–3309. [PubMed: 12109913]
25. Watkins, CJ.; Romero-Martin, M.; Moore, KG.; Ritchie, J.; Finn, PW.; Kalvinsh, I.; Loza, E.; Starchenkov, I.; Dikovska, K.; Bokaldere, RM.; Gailite, V.; Vorona, M.; Andrianov, V.; Lolya, D.; Semenikhina, V.; Amolins, A.; Harris, CJ.; Duffy, JE. Prolifix Limited; United Kingdom: 2002. WO 02/026696A1
26. Chen B, Petukhov PA, Jung M, Velen A, Eliseeva E, Dritschilo A, Kozikowski AP. *Bioorg. Med. Chem. Lett* 2005;15:1389–1392. [PubMed: 15713393]
27. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M. *Biochem. J.* in pressdoi:10.1042 /BJ20070779
28. Glaser KB, Li J, Pease LJ, Staver MJ, Marcotte PA, Guo J, Frey RR, Garland RB, Heyman HR, Wada CK, Vasudevan A, Michaelides MR, Davidsen SK, Curtin ML. *Biochem. Biophys. Res. Commun* 2004;325:683–690. [PubMed: 15541343]
29. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu, Chumakov A, Imai Y, Koeffler HP. *Int. J. Cancer* 2007;121:656–665. [PubMed: 17417771]
30. Fujita T, Iwasa J, Hansch C. *J. Am. Chem. Soc* 1964;86:5175–5180.

Scheme 1.

Synthesis of ligands **7a-g**: **a**, POCl₃, pyridine, -15 °C, 1 h, **2** (**a** = BOC-Gly-OH, **b** = BOC-*L*-Phe-OH, **c** = BOC-*L*-Pro-OH, **d** = BOC-*L*-Trp-OH, **e** = BOC-*L*-Tyr(Bn)-OH, **f** = BOC₂O, **g** = BOC-*D*-Phe-OH); for **2f**: toluene 100 °C, overnight; **b**, H₂, Pd(OH)₂-C, rt, 4 h; for **3g**: SnCl₂, methanol-dioxane, reflux, overnight; **c**, **5** (7-Benzyloxycarbonylheptanoic acid), PyBOP, DIPEA, DMF, rt, overnight; **d**, for **7a-f** (**a**, R = Gly-, **b**, R = *L*-Phe-, **c**, R = *L*-Pro-, **d**, R = *L*-Trp-, **e**, R = *L*-Tyr-, **f**, R = H): i) TFA, ii), H₂, Pd(OH)₂-C, 4 h; for **7g** (R = BOC): Pd (OH)₂-C, 4 h.

Scheme 2.

Synthesis of ligands **10a-d** and **11**: a, **8** (6-(2-Tritylsulfanylacetyl-amino)hexanoic acid), PyBOP, DIPEA, DMF, rt, overnight; b, TFA, Et₃SiH, 0 °C, 2 h; c, i) TFA, Et₃SiH, 0 °C, 2 h, ii) H₂, Pd(OH)₂-C, rt, 10 h.

Scheme 3.

Synthesis of ligands **16a**, **16b**, **17a**, **17b**, **21** and **23**: a, POCl₃, pyridine, suberic acid monomethyl ester, -15 °C, 1 h; b, H₂, Pd-C, EtOH, AcOH, 50 °C, 2 h; c, LiOH; d, NH₂OH, KOH, MeOH, rt, 1 h; e, i) *i*-Butyl chloroformate, Et₃N, 0 °C, ii) NH₂OH; f, EEDQ, BOC-Gly-OH; g, LiOH; h, THPONH₂, EDCI, HOBT, Et₃N, rt; i, TFA; j, LiOH; k, i) Ethyl chloroformate, Et₃N, 0 °C, ii) NH₂OH.

Scheme 4.

Synthesis of ligands **25a**, **25b**, **27** and **29**: a, BOC₂O, THF, reflux, overnight; b, NH₂OH, KOH, MeOH, rt, 1 h; c, trimethylacetic anhydride, THF, reflux, overnight; d, NH₂OH, KOH, MeOH, rt, 1 h; e, cyclohexanecarbonyl chloride, THF, reflux, overnight; f, NH₂OH, KOH, MeOH, rt, 1 h.

Figure 1.

Figure 2.

(a) A plot between the observed and the calculated pIC_{50} values against HDAC1 using eq. 1. Eq. 1 shows that the three classes explain 92% of the variance of the inhibitory activity data. The influences of the CAP groups among each of the classes are relatively small and may be involved in the remaining variance of the data. (b) A plot between the observed and the calculated pIC_{50} values against HDAC6 using eq. 5. (c) A plot between the observed and the calculated pIC_{50} values against the selectivity of HDAC6 over HDAC1 using eq. 6.

Table 1
HDACs inhibitory activity (IC₅₀, nM)^[a] of the biphenyl bearing hydroxamates, mecaptoacetamides, SAHA^[b] and TSA.

Compd	R	HDAC1	HDAC2	HDAC3	HDAC8	HDAC10	HDAC6
SAHA ^[b]	-	68	164	48	1524	NA ^[d]	90
TSA	-	4	14	2	1380	5	1
7h	H	33	46	7	1870	46	5
7g	NH ₂	99	244	ND ^[c]	2500	139	16
7f		57	74	18	1720	83	11
7a		102	364	ND	3480	146	28
7b		41	156	ND	1600	46	8
7c		52	193	ND	2660	70	16
7d		27	167	ND	1720	28	5

		7a-h		10a-d			
Compd	R	HDAC1	HDAC2	HDAC3	HDAC8	HDAC10	HDAC6
7e		37	205	ND	2060	42	9
10a		3960	15980	ND	6030	7430	387
10b		2760	>30000	ND	5190	7220	452
10c		1950	12490	ND	4230	6070	205
10d		7090	>30000	4330	11250	>30000	656

[a]₁ The isoform inhibition was tested at Amphora Discovery Corporation (<http://www.amphoracorp.com/>).

[b]₁ Taken from reference 27.

[c]₁ ND = Not determined.

[d]₁ NA = Not available.

Table 2
HDACs inhibitory activity (IC₅₀, nM)^(a) of the phenylthiazole bearing hydroxamates.

Compd	R	HDAC1	HDAC2	HDAC3	HDAC8	HDAC10	HDAC6
24	H	3	35	ND ^(a)	1900	4	3
16a	NO ₂	38	222	ND	3930	44	8
16b	NO ₂	9	113	ND	4090	11	4
17a	NH ₂	3	14	2	1430	3	3
17b	NH ₂	4	27	ND	1950	4	3
21		2	19	2	1940	3	1
23		3	25	1	787	2	0.8
25a		12	42	4	1850	14	4
25b		4	21	2	2580	6	<0.2

Compd	R	HDAC1	HDAC2	HDAC3	HDAC8	HDAC10	HDAC6
27		11	46	6	1990	14	2
29		2	<0.2	<0.2	3950	4	<0.2

**16b, 17b,
21, 23, 25b, 27, 29**

16a, 17a, 24, 25a

[a] The isoform inhibition was tested at Amphora Discovery Corporation (<http://www.amphoracorp.com/>).

[b] ND = Not determined.

Table 3
Antiproliferative activities (IC_{50} , μM) of SAHA and biaryl HDAC inhibitors against pancreatic cell lines.

Compd	Pancreatic cancer cell lines				
	BxPC-3	HupT3	Mia Paca-2	Panc 04.03	SU 86.86
SAHA	5	0.8	1.1	1.2	1.3
7g	7	1	0.2	3	1
7b	10	10	<1	10	10
7c	33	23	3	32	23
7e	>50	25	1	>50	55
16a	5	2	0.2	3	1
17a	2	<1	<1	2	1
17b	1	0.6	0.01	>10	3
23	1	0.7	0.04	0.6	2

Table 4 HDACs inhibitory activity (IC₅₀, nM) of biphenyl and phenylthiazole analogs bearing hydroxamates or mercaptoacetamides.

Compd	HDAC1		HDAC2		HDAC8		HDAC10		HDAC6		CLogP	I-NHCOC H ₂ SH	I-Thiazole
	IC ₅₀	pIC ₅₀	IC ₅₀	pIC ₅₀	IC ₅₀	pIC ₅₀	IC ₅₀	pIC ₅₀	IC ₅₀	pIC ₅₀			
7h	33	7.48	46	7.34	1870	5.73	46	7.34	5	8.30	2.877	0	0
7g	99	7.00	244	6.61	2500	5.60	139	6.86	16	7.80	1.650	0	0
7f	57	7.24	74	7.13	1720	5.76	83	7.08	11	7.96	3.583	0	0
7a	102	6.99	364	6.44	3480	5.46	146	6.84	28	7.55	-0.045	0	0
7b	41	7.39	156	6.81	1600	5.80	46	7.34	8	8.10	1.682	0	0
7c	52	7.28	193	6.71	2660	5.58	70	7.15	16	7.80	0.969	0	0
7d	27	7.57	167	6.78	1720	5.76	28	7.55	5	8.30	1.672	0	0
7e	37	7.43	205	6.69	2060	5.69	42	7.38	9	8.05	1.015	0	0
10a	3960	5.40	15980	4.80	6030	5.22	7430	5.13	387	6.41	-0.574	1	0
10b	2760	5.56	>30000	<4.52	5190	5.28	7220	5.14	452	6.34	1.153	1	0
10c	1950	5.71	12490	4.90	4230	5.37	6070	5.22	205	6.69	0.440	1	0
10d	7090	5.15	>30000	<4.52	11250	4.95	>30000	<4.52	656	6.18	1.143	1	0
24	3	8.52	35	7.46	1900	5.72	4	8.40	3	8.52	2.323	0	1
16a	38	7.42	222	6.65	3930	5.41	44	7.36	8	8.10	2.323	0	1
17a	3	8.52	14	7.85	1430	5.84	3	8.52	3	8.52	1.290	0	1
16b	9	8.05	113	6.95	4090	5.39	11	7.96	4	8.40	2.084	0	1
17b	4	8.40	27	7.57	1950	5.71	4	8.40	3	8.52	1.290	0	1
21	2	8.70	19	7.72	1940	5.71	3	8.52	1	9.00	0.910	0	1
23	3	8.52	25	7.60	787	6.10	2	8.70	0.8	9.10	2.467	0	1
25a	4	8.40	21	7.68	2580	5.59	6	8.22	<0.2	9.70*	3.175	0	1
25b	12	7.92	42	7.38	1850	5.73	14	7.85	4	8.40	3.175	0	1
27	11	7.96	46	7.34	1990	5.70	14	7.85	2	8.70	2.758	0	1
29	2	8.70	<0.2	>9.70	3950	5.40	4	8.40	<0.2	9.70 ^[a]	3.552	0	1

^[a]The IC₅₀ value 0.2 was used in the correlations.

QSAR equations developed from the 23 biphenyl or phenylthiazoles bearing hydroxamates or mercaptoacetamides listed in Table 1, 2, and 4 against HDAC1, HDAC2, HDAC8, HDAC10, and HDAC6, respectively (Equations 1 – 5). Equations 6 – 9 are for the selectivity of the inhibitory activity (pIC_{50}) of HDAC6 with respect to those of HDAC1, HDAC2, HDAC10, and HDAC8 (Equations 6 – 9b).

Table 5

Equations	n	R ²	RMSE	p
(1) pIC_{50} (HDAC1) = $-1.844(\pm 0.248)$ I-NHCOCH ₂ SH + $0.983(\pm 0.1149)$ I-Thiazole + $7.299(\pm 0.114)$	23	0.920	0.322	<0.0001
(2) pIC_{50} (HDAC2) = $-1.963(\pm 0.258)$ I-NHCOCH ₂ SH + $0.606(\pm 0.155)$ I-Thiazole + $6.813(\pm 0.115)$	20	0.860	0.326	<0.0001
(2a) pIC_{50} (HDAC2) = $-2.127(\pm 0.195)$ I-NHCOCH ₂ SH + $0.606(\pm 0.151)$ I-Thiazole + $6.813(\pm 0.112)$	22	0.918	0.318	<0.0001
(3) pIC_{50} (HDAC8) = $-0.461(\pm 0.097)$ I-NHCOCH ₂ SH + $5.668(\pm 0.040)$	23	0.518	0.176	<0.0001
(4) pIC_{50} (HDAC10) = $-2.029(\pm 0.222)$ I-NHCOCH ₂ SH + $1.007(\pm 0.153)$ I-Thiazole + $7.192(\pm 0.116)$	22	0.916	0.328	<0.0001
(5) pIC_{50} (HDAC6) = $-1.429(\pm 0.246)$ I-NHCOCH ₂ SH + $0.711(\pm 0.184)$ I-Thiazole + $0.046(\pm 0.023)$ (ClogP) ² + $7.799(\pm 0.163)$	23	0.861	0.384	<0.0001
(6) pIC_{50} (HDAC6) = $0.767(\pm 0.053)$ pIC_{50} (HDAC1) + $0.046(\pm 0.014)$ (ClogP) ² + $2.178(\pm 0.374)$	23	0.943	0.241	<0.0001
(6a) pIC_{50} (HDAC6) = $0.844(\pm 0.057)$ pIC_{50} (HDAC1) + $1.804(\pm 0.432)$	23	0.911	0.292	<0.0001
(7) pIC_{50} (HDAC6) = $0.726(\pm 0.104)$ pIC_{50} (HDAC2) + $0.275(\pm 0.167)$ I-Thiazole + $3.032(\pm 0.674)$	20	0.863	0.294	<0.0001
(7a) pIC_{50} (HDAC6) = $0.832(\pm 0.085)$ pIC_{50} (HDAC2) + $2.435(\pm 0.594)$	20	0.849	0.307	<0.0001
(8) pIC_{50} (HDAC6) = $0.681(\pm 0.060)$ pIC_{50} (HDAC10) + $0.053(\pm 0.016)$ (ClogP) ² + $2.892(\pm 0.425)$	22	0.914	0.272	<0.0001
(8a) pIC_{50} (HDAC6) = $0.760(\pm 0.068)$ pIC_{50} (HDAC10) + $2.539(\pm 0.508)$	22	0.863	0.335	<0.0001
(9) pIC_{50} (HDAC6) = $1.650(\pm 0.447)$ pIC_{50} (HDAC8) + $0.880(\pm 0.227)$ I-Thiazole + $0.067(\pm 0.028)$ (ClogP) ² - $1.840(\pm 2.459)$	23	0.775	0.489	<0.0001
(9a) pIC_{50} (HDAC6) = $1.834(\pm 0.489)$ pIC_{50} (HDAC8) + $1.059(\pm 0.238)$ I-Thiazole - $2.633(\pm 2.701)$	23	0.709	0.542	<0.0001
(9b) pIC_{50} (HDAC6) = $2.498(\pm 0.642)$ pIC_{50} (HDAC8) - $5.863(\pm 3.589)$	23	0.419	0.747	<0.0008

Table 6

Observed and calculated HDACs inhibitory activity (IC₅₀, nM) of biphenyl and phenylthiazole analogs bearing hydroxamates or mercapto-acetamides.

Compd	pIC ₅₀ (HDAC1)				pIC ₅₀ (HDAC2)				pIC ₅₀ (HDAC8)				pIC ₅₀ (HDAC10)				pIC ₅₀ (HDAC6)			
	obs ^a	cal ^e	dev ^a	obs ^b	cal ^b	dev ^b	obs ^c	cal ^c	dev ^c	obs ^d	cal ^d	dev ^d	obs ^e	cal ^e	dev ^e	obs ^f	cal ^f	dev ^f	obs ^g	cal ^g
7h	7.48	7.30	0.18	7.34	6.81	0.52	5.73	5.67	0.06	7.34	7.19	0.15	8.30	8.18	0.12	8.30	8.18	0.12	8.30	8.18
7g	7.00	7.30	-0.29	6.61	6.81	-0.20	5.60	5.67	-0.07	6.86	7.19	-0.33	7.80	7.93	-0.13	7.80	7.93	-0.13	7.80	7.93
7f	7.24	7.30	-0.06	7.13	6.81	0.32	5.76	5.67	0.10	7.08	7.19	-0.11	7.96	8.39	-0.43	7.96	8.39	-0.43	7.96	8.39
7a	6.99	7.30	-0.31	6.44	6.81	-0.37	5.46	5.67	-0.21	6.84	7.19	-0.36	7.55	7.80	-0.25	7.55	7.80	-0.25	7.55	7.80
7b	7.39	7.30	0.09	6.81	6.81	-0.01	5.80	5.67	0.13	7.34	7.19	0.15	8.10	7.93	0.17	8.10	7.93	0.17	8.10	7.93
7c	7.28	7.30	-0.02	6.71	6.81	-0.10	5.58	5.67	-0.09	7.15	7.19	-0.04	7.80	7.84	-0.05	7.80	7.84	-0.05	7.80	7.84
7d	7.57	7.30	0.27	6.78	6.81	-0.04	5.76	5.67	0.10	7.55	7.19	0.36	8.30	7.93	0.37	8.30	7.93	0.37	8.30	7.93
7e	7.43	7.30	0.13	6.69	6.81	-0.13	5.69	5.67	0.02	7.38	7.19	0.19	8.05	7.85	0.20	8.05	7.85	0.20	8.05	7.85
10a	5.40	5.46	-0.05	4.80	4.85	-0.05	5.22	5.21	0.01	5.13	5.16	-0.03	6.41	6.39	0.03	6.41	6.39	0.03	6.41	6.39
10b	5.56	5.46	0.10	<4.52	4.85*	>-0.33	5.28	5.21	0.08	5.14	5.16	-0.02	6.34	6.43	-0.09	6.34	6.43	-0.09	6.34	6.43
10c	5.71	5.46	0.25	4.90	4.85	0.05	5.37	5.21	0.17	5.22	5.16	0.05	6.69	6.38	0.31	6.69	6.38	0.31	6.69	6.38
10d	5.15	5.46	-0.31	<4.52	4.85*	>-0.33	4.95	5.21	-0.26	<4.52	5.16*	>-0.64	6.18	6.43	-0.25	6.18	6.43	-0.25	6.18	6.43
24	8.52	8.28	0.24	7.46	7.42	0.04	5.72	5.67	0.05	8.40	8.20	0.20	8.52	8.76	-0.24	8.52	8.76	-0.24	8.52	8.76
16a	7.42	8.28	-0.86	6.65	7.42	-0.77	5.41	5.67	-0.26	7.36	8.20	-0.84	8.10	8.76	-0.66	8.10	8.76	-0.66	8.10	8.76
17a	8.52	8.28	0.24	7.85	7.42	0.43	5.84	5.67	0.18	8.52	8.20	0.32	8.52	8.59	-0.06	8.52	8.59	-0.06	8.52	8.59
16b	8.05	8.28	-0.24	6.95	7.42	-0.47	5.39	5.67	-0.28	7.96	8.20	-0.24	8.40	8.71	-0.31	8.40	8.71	-0.31	8.40	8.71
17b	8.40	8.28	0.12	7.57	7.42	0.15	5.71	5.67	0.04	8.40	8.20	0.20	8.52	8.59	-0.06	8.52	8.59	-0.06	8.52	8.59
21	8.70	8.28	0.42	7.72	7.42	0.30	5.71	5.67	0.04	8.52	8.20	0.32	9.00	8.55	0.45	9.00	8.55	0.45	9.00	8.55
23	8.52	8.28	0.24	7.60	7.42	0.18	6.10	5.67	0.44	8.70	8.20	0.50	9.10	8.79	0.31	9.10	8.79	0.31	9.10	8.79
25a	8.40	8.28	0.12	7.68	7.42	0.26	5.59	5.67	-0.08	8.22	8.20	0.02	9.70 [†] *	8.98	0.72	9.70 [†] *	8.98	0.72	9.70 [†] *	8.98
25b	7.92	8.28	-0.36	7.38	7.42	-0.04	5.73	5.67	0.07	7.85	8.20	-0.34	8.40	8.98	-0.58	8.40	8.98	-0.58	8.40	8.98
27	7.96	8.28	-0.32	7.34	7.42	-0.08	5.70	5.67	0.03	7.85	8.20	-0.34	8.70	8.86	-0.16	8.70	8.86	-0.16	8.70	8.86
29	8.70	8.28	0.42	>9.70	7.42*	>2.28	5.40	5.67	-0.26	8.40	8.20	0.20	9.70 [†]	9.09	0.61	9.70 [†]	9.09	0.61	9.70 [†]	9.09

^a Calculated using eq. 1.

^b Calculated using eq. 2.

^c Calculated using eq. 9.

^d Calculated using eq. 3.

^e Calculated using eq. 4.

^{*} Not used in the correlation.

^f Based on the IC₅₀ of 0.2 nM.